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Abstract
O-linked β-N-acetylglucosamine is a regulatory post translational
modification. This modification occurs on nearly all functional classes of proteins,
in the nucleus and cytoplasm. O-GlcNAc is added to serine or threonine by OGlcNAc transferase and removed by O-GlcNAcase. Previous attempts to study
O-GlcNAc-modified proteins have resulted in low yields, making 3-dimensional
structure determination impossible. In this dissertation O-GlcNAc transferase will
be co-expressed with domains of human cAMP responsive element-binding
protein (CREB1) and Abelson tyrosine-kinase 2 (ABL2) in E. coli, to produce OGlcNAc-modified protein. The O-GlcNAc-modified protein was expressed in a
variety of E. coli cell lines at a variety of conditions, but only small quantities of
insoluble protein were produced. A glycosidase was suspected due to the
disappearance of the O-GlcNAc modification from the protein. O-(2-acetamido-2dexoy-dglucopyranosylidene) amino-N-phenylcarbamate (PUGNAc), a β-Nacetylglucosaminidase inhibitor, was added to the culture media and increased
the production of O-GlcNAc-modified protein. This was the first evidence that βN-acetylglucosaminidase (NagZ), an E. coli enzyme, cleaves O-GlcNAc from
proteins in vivo. NagZ was isolated and shown to cleave O-GlcNAc from a
synthetic O-GlcNAc-peptide in vitro. In E. coli, NagZ cleaves the GlcNAc-β1,4N-acetylmuramic acid linkage to recycle peptidoglycan in the cytoplasm. A
NagZ knockout showed no activity towards the O-GlcNAc-peptide, confirming
NagZ as the enzyme responsible for cleaving O-GlcNAc from our glycoprotein
expressed in vivo. O-GlcNAc-modified protein produced by the NagZ knockout
(∆NagZ) co-expression system is highly glycosylated and can be resolubilized
xv

from the pellet. The ∆NagZ is a step closer to production of milligram quantities
of O-GlcNAc-modified protein for structure determination.

xvi

Chapter 1: Background
1. 1 Proteins
Proteins are macromolecules that are present in all living systems. They which
play essential roles in many cellular processes such as transport, storage, cellular
signaling and immune response [1]. A major class of proteins, known as enzymes, act
as catalyst for many chemical reactions in biological systems. They are composed of 20
amino acid building blocks. These amino acids, containing a carboxyl end, amino end
and side chain, are linked together when a dehydration reaction occurs between two
amino acids and forms a peptide bond (Figure 1-1).

Figure 1-1 Synthesis and structure of the peptide backbone. http://www.
molecularsciences. org/book/export/html/253
Proteins are synthesized through two processes called transcription and
translation. During transcription, RNA polymerase transcribes single strands of DNA into
complimentary strands of RNA called messenger RNA (mRNA). The mRNA is then
translated into a polypeptide chain by ribosomes, composed of ribosomal proteins,

1

ribosomal RNA (rRNA), and transfer RNA (tRNA). tRNA is unlike mRNA in that it carries
amino acids. One side of tRNA has nucleotide base pairs and the other has the amino
acids that correspond to the nucleotide base pairs. The ribosome synthesizes a protein
by reading mRNA, binding the appropriate tRNA, and creating peptide bonds between
each amino acid (Figure1-2) [2].

Figure 1-2 Transcription and translation of proteins. http://www. tokresource.
org/tok_classes/biobiobio/biomenu/transcription_translation/
1. 2 Protein Structure
The overall 3-dimensional (3D) structure or tertiary structure of a protein is
dependent upon its primary and secondary structure. The primary structure of a protein
is its amino acid sequence. The secondary structure describes how this chain of amino
acids behave in relation to their bond neighbor. Secondary structure consists of alpha
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helices, beta sheets and non-structured regions called loops. Alpha helices form a
spiral-like shape with 3. 6 amino acids for every turn. The protein backbone forms the
inside of the coil with the amino acid side chains at the exterior. The spiral or coil shape
is stabilized by intramolecular hydrogen bonds formed between the amide group
hydrogen and the oxygen of a carboxyl group 4 residues away (Figure 1-3). Beta sheets
are flat or linear in shape and are also held together by hydrogen bonds. These bonds
differ from those in the alpha helix in that they occur between separate chains. Also, the
intramolecular hydrogen bond is between the hydrogen of an amide on one chain and
the oxygen of a carboxyl of a neighboring chain. The alpha helices, beta sheet and
loops fold to make subunits of the proteins. These subunits describe a protein’s 3D
tertiary structure. Finally, these tertiary structures of protein monomers fit together to
make protein complexes or multimers. The structures resulting from these multimers is
quaternary structure, which is the overall folded state of the entire complex (Figure1-3).
The tertiary and quaternary structures are held together by hydrogen bonds, ionic
bonds, hydrophobic interactions and disulfide bonds between side chains [3].
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Figure 1-3 Protein structure. https://www. mun. ca/biology/scarr/iGen3_06-04. html
1. 3 Protein function as it relates to structure
Protein function depends on protein structure. In most cases, proteins have to be
folded in a certain conformation to carry out their function. For example, in lock and key
ligand binding, enzymes show specificity for substrates by forming an active cite based
on the enzyme’s structure. This substrate binding event is often part of a cascade of
events required for function to take place [3].
1. 4 Post translational modifications
A post translation modification (PTM) is a covalent chemical modification that
occurs after the protein has been translated. There are many types of PTMs, such as
methylation, ubiquitination, phosphorylation, and glycosylation. Methylation adds a
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methyl group to a lysine or arginine. Ubiquitination is the addition of an entire ubiquitin
protein molecule to a lysine residue. Phosphorylation and glycosylation are the two
most common PTMs. Phosphorylation is the addition of a phosphate at a serine and/or
threonine residue. Glycosylation can be N-linked and O-linked. N-linked glycosylation
normally consists of the addition of a polysaccharide chain at an asparagine, as long as
the asparagine is part of a tri-peptide motif consisting of the asparagine, any amino acid
and then a serine or threonine (N, X, S/T). This consensus sequence is a tri-peptide
within the sequence of the protein where the N-linked glycosylation may occur.
Knowledge of this consensus sequence allows us to predict possible glycosylation sites.
Most O-linked glycosylations are similar to N-linked glycosylations, in that they are long
chain polysaccharides. The exception is O-linked N-acetylglucosamine (O-GlcNAc),
which is the addition of a monosaccharide instead of a polysaccharide [4].
1. 5 O-GlcNAc in the hexosamine biosynthesis pathway
The hexosamine biosynthesis pathway (HBP) is a metabolic pathway that
produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the substrate for OGlcNAcylation, and other nucleotide hexosamines (Figure 1-4). Hexosamines, also
called amino sugars, are sugars that have an amino group (-NH2) in place of a hydroxyl
group. The HBP varies based on the organism. In humans, glucose enters the cell and
is phosphorylated by hexokinase. Only 2-5% of glucose that enters the cell enters the
HBP, therefore the level of O-GlcNAcylation is dependent on nutrient availability [5].
Once glucose is phosphorylated and converted to fructose-6-phosphate, it can enter the
HBP or the main glycolytic/glycogen pathway. The HBP is initiated by
glutamine/fructose aminotransferase (GFAT). GFAT is an enzyme that transfers an
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amino group to fructose-6-phophate from the amino acid glutamine, producing
glucosamine-6-phosphate [6]. It is important to add that glucosamine-6-phophate can
also be produced by glucosamine that enters the cell and is phosphorylated by
hexokinase [7]. EMeg32, a glucosamine-6-phospate N-acetyltransferase, in an enzyme
that acetylates glucosamine-6-phosphate using acetyl-CoA as a substrate [8]. Nacetylglucosamine-6-phosphate, produced by the acetylation reaction, is interconverted
to N-acetylglucosamine-1-phosphate by N-acetyl phospho-glucosamine mutase
(AGM1). N-acetylglucosamine-1-phosphate is finally uridylated to UDP-GlcNAc by UDPGlcNAc pyrophosphorylase (UAP1) [9].
1. 6 O-GlcNAc is not your typical glycosylation
O-GlcNAc is an O-linked glycosylation that occurs at a serine or a threonine. O-GlcNAc
is cycled on and off of protein substrates by enzymes. It is added by the enzyme OGlcNAc transferase (OGT) and remove by O-GlcNAcase (OGA) (Figure 1-5) [10]. This
O-linked modification is unlike most glycosylation. Only one sugar is added, as opposed
to a longer polysaccharide chain. There is no consensus sequence recognized by OGT,
which makes O-GlcNAc-site prediction difficult [11]. O-GlcNAc has a reciprocal
relationship with phosphorylation. They can occur on the same protein at the same time
or at a specific residue interchangeably [12]. This relationship with phosphorylation is
used by most prediction algorithms to identify possible O-GlcNAc modification sites [12].
In mammals, most protein glycosylation occurs in the extracellular matrix or the
secretion pathway. However, O-GlcNAc can be found in the cytoplasm, nucleus and
mitochondria.
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Figure 1-4 The HBP pathway in humans. Yuzwa, S. A. and D. J. Vocadlo, O-glcnac and
neurodegeneration: Biochemical mechanisms and potential roles in alzheimer's disease
and beyond. Chemical Society Reviews, 2014. 43(19): p. 6839-6858.
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Figure 1- 5 Enzymatic cycling of O-GlcNAc by OGT and OGA. Hart, G. W. , M. P.
Housley, and C. Slawson, Cycling of o-linked beta-n-acetylglucosamine on
nucleocytoplasmic proteins. Nature, 2007. 446(7139): p. 1017-22.
1. 7 O-GlcNAc is a regulatory enzyme that is implicated in disease when it is
dysregulated
The O-GlcNAc modification was first discovered by Gerald Hart in 1984 and is
dynamic and regulatory in nature [13]. O-GlcNAc-modified proteins regulate many
biological processes, such as transcription, translation, protein degradation, cell
signaling, cell trafficking, apoptosis and cell cycle control [14]. It also regulates some
physiological events, such as the circadian rhythm, memory formation, and learning
[15]. When the OGT gene is knocked out in mice, it is embryonic lethal, therefore this
regulatory modification is essential for life [16].
Cyclic AMP-response element binding protein 1 (CREB1) is a transcription factor
that binds to TATA-associated factor (TafII130), a coactivator, to induce transcription of
the cyclic AMP response element (CRE) gene [17]. When O-GlcNAc is bound to
CREB1, association with TafII130 is inhibited and transcription is repressed [17].
Repression of the CRE gene leads to reduced growth in axons and dendrites in mice
brain cells [18]. Axon and dendrite growth and connection is how memories are formed.
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Dysregulated O-GlcNAcylation of CREB1 leads to memory loss in mice and has been
linked to Alzheimer’s disease [20].
In the brain, neurons (brain cells) consist of a cell body, dendrites, and axons.
The neuronal cell body is very similar to other cells and contains the nucleus, cytoplasm
and cellular membrane. Dendrites carry information into the cell body through electric
signals, while axons take information away from the cell body. Dendrites are connected
to the cell body at one end while the axons are at the opposite end of the cell body [21].
Microtubules are the major structural component of axons. They play a key role in
intracellular transport by carrying nutrients and other cellular cargo [21]. They are hollow
and tubular in shape and are composed of polar filamentous polymers of α/β tubulin
heterodimers. These microtubules are held together by MT binding proteins such as
tau. Hyperphosphorylated tau separates tau from the microtubules, causing them to fall
apart [22]. The hyperphosphorylated tau molecules aggregate within the neuron,
causing tangles, inhibiting neurotransmission and destroying the cell [23]. The OGlcNAc modification can compete with phosphorylation sites on tau. When OGA is
inhibited in rodents, the O-GlcNAc modification increases and the phosphorylation
decreases at pathologically relevant sites on Tau [23]. This increase in O-GlcNAcylation
blocks hyperphosphorylation and hinders aggregation [24].
O-GlcNAc also plays a role in diabetes and cancer. Recent research has
suggested that an increase of the O-GlcNAc modification in prostate cancer cells
promotes the progression of tumor cells. This elevation of O-GlcNAc is associated with
an increase in overall patient expiration [25]. Elevated O-GlcNAc levels have also been
shown to enhance migration/invasion and metastasis in breast cancer cells [26]. Over
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expression of OGT, the enzyme that adds O-GlcNAc; and GFAT, the rate limiting step
of the HBP; in various tissues leads to insulin resistance in mice [27]. Insulin is a
hormone that carries glucose from the bloodstream into cells. Insulin resistance refers
to the decreased efficiency of insulin for glucose uptake, metabolism and storage.
Insulin resistance is a major feature and cause of Type 2 diabetes [28].
1. 8 Inhibitors of hexosaminidase
O-GlcNAcase is a hexosaminidase that removes the O-GlcNAc modification from
substrate proteins. Hexosaminidases are enzymes that remove hexosamines. There
are several different hexosaminidases. When analyzing the O-GlcNAc modification in
cells that contain a hexosaminidase, it is often necessary to inhibit the hexosaminidase
in order to increase glycosylation and analyze the effect of hyperglycosylation.
Streptozotocin (STZ) was one of the first OGA inhibitors used [29]. Recent research
suggest that STZ acts as a chemical poison rather than an OGA inhibitor [5]. O-(2Acetamido-2-deoxy-D-glucopyranosylidenamino) amino-N-phenylcarbamate (PUGNAc)
is another inhibitor of OGA with a Ki value of 50 nM for OGT purified from rats [5].
Although PUGNAc inhibits OGA, it is not specific to OGA and inhibits other
glycosidases [30]. PUGNAc inhibits lysosomal hexosaminidase with a Ki of 30-40 nM
[5]. Thiamet-G has a Ki of 21 nM for OGA and is a stable bioactive inhibitor, leading to
increased tau glycosylation in mice brain [31]. In an effort to create a strong and
selective inhibitor, Dorfmuller and coworkers developed a class of small molecule OGA
inhibitors called GlcNAcstatins [32]. This class of inhibitors is more selective towards
human OGA and increases O-GlcNAcylation by 2 to 3 fold [5].
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1. 9 Methods for O-GlcNAc detection
1. 9. 1 Galactosyltransferase-based methods
Β-1,4-Galactosyltransferase is an enzyme that transfers a single galactose from
UDP-galactose to a terminal GlcNAc molecule (Figure 1-6b). This enzymatic labeling
method was used in 1984 by Gerald Hart when he first discovered the O-GlcNAc
modification [13]. Radioactive 3H-galactose was added to O-GlcNAcylated proteins and
the radioactivity was detected. This technique can be used to transfer a galactose with a
chemically reactive group to the O-GlcNAc residue [33]. This allows for biotin labeling,
which can then be used for chemiluminescent and western blot detection, or enrichment
for further analysis.

1. 9. 2 Lectin blot
A lectin blot is a technique in which a lectin is used to detect a glycoprotein
(Figure 1-6a). The lectin, which is a protein that recognizes and binds a specific
carbohydrate and binds carbohydrate based molecules, is conjugated to a fluorescent
tag for detection. Lectins are found in most animals, plants and microorganisms. Wheat
germ agglutinin (WGA) is the lectin that recognizes and binds to terminal GlcNAc or Nacetylneuraminic acid residues [34]. WGA is bound to agarose beads and used as a
means of affinity purification in order to enrich the glycoprotein for further analysis.
Although WGA binds O-GlcNAc, it is not always selective. For this reason, other means
of detection are sometimes necessary.
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1. 9. 3 Western blot
Western blots are very similar to lectin blots. Instead of using a lectin to bind and
detect the protein of interest, primary and secondary antibodies are used (Figure 1-6a).
Proteins are transferred from a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel onto a nitrocellulose or PVDF membrane. The
membrane is then blocked. The term blocked refers to the blocking of free space on the
membrane to insure proper antibody binding. The membrane is probed with the primary
antibody. This antibody binds to the epitope of interest. CTD 110. 8 and RL-2 are
common antibodies for the detection of O-GlcNAc. CTD 110. 8 binds specifically to OGlcNAc while RL2 less specific. A secondary antibody, which is conjugated to a
fluorescent tag, binds the primary antibody. Although this method of detection is very
similar to a lectin blot, it is more selective.

1. 9. 4 Chemical Derivatization – BEMAD
Mass spectrometry (MS) techniques that use high energy ionization methods
tend to fragment the O-GlcNAc modification before it can be analyzed. In 2002 Lance
Wells applied the beta elimination Michael addition (BEMAD) reaction, a two-step
organic reaction, to O-GlcNAc-modified proteins [35]. The BEMAD reaction replaces the
O-GlcNAc modification with another compound that is stable during MS analysis. The
first step of the reaction is the beta elimination of O-GlcNAc, followed by the addition of
a new compound via Michael addition of a nucleophile. Dithiothreitol (DTT) or biotin
pentylamine (BAP) are the nucleophiles of that have been used [36]. At the time, this
reaction was notable because it allowed detection of O-GlcNAc-modified protein and
site mapping. Site mapping is a process where the exact amino acid modified is
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identified. Now, there are lower energy fragmentation techniques that allow the OGlcNAc modification to stay intact during site mapping [35].

Figure 1-6 Methods of O-GlcNAc detection. Banerjee, P. S. , G. W. Hart, and J. W. Cho,
Chemical approaches to study o-glcnacylation. Chemical Society Reviews, 2013.
42(10): p. 4345-4357
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1. 10 Methods to study O-GlcNAc-modified proteins
There have been numerous strategies to study O-GlcNAc-modified proteins. OGlcNAc-modified proteins have been extracted from animal tissues. OGT has been
extracted and used for in vitro glycosylation. OGT has been expressed in E. coli and
used for in vitro glycosylation. Target proteins have been expressed in human cells that
have the OGT gene. The aim of methods is to identify O-GlcNAc-modified proteins.
WGA affinity chromatography is often used to enrich protein samples. The sites of
glycosylation are then mapped using MS. Mice and fly have been used to study to
effects of the O-GlcNAc modification on cellular processes related to a specific protein
[37, 38].

1. 11 Challenges
Although there have been major discoveries about the O-GlcNAc modification
since it was first discovered, there are still many limitations. The greatest of these is the
sample size. Proteins extracted from animal tissue are low in concentration. The same
is true for modified proteins expressed in human cells. In vitro reactions are
normally done on a small scale due to the low concentration of extracted OGT. Human
OGT expressed in E. coli has also been used for in vitro glycosylation reactions. Limited
sample concentration has made structural analysis of O-GlcNAc-modified proteins
impossible. NMR and X-ray crystallography require milligram quantities of protein when
the methods to date yield only micrograms of O-GlcNAc-modified protein.
1. 12 In vivo expression of O-GlcNAc-modified protein
Dysregulation of the O-GlcNAc modification, whether too much or too little, has
been implicated in disease. Given that the modification is essential for life and has been
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linked to several diseases, understanding the effect of the modification on protein
structure is imperative. In this thesis, O-GlcNAc-modified proteins will be expressed in
vivo. In this particular method, OGT and a target protein are co-expressed in E. coli.
This method is especially interesting because it enables the expression of large
amounts of modified target proteins. More importantly, this method allows isotopic
labeling for NMR structural analysis. E. coli was chosen over mammalian or insect cells
because it does not carry the OGT gene. E. coli is the most common expression system
for milligram quantities of protein for NMR and X-ray crystallography structural analysis
[39]. This method requires molecular cloning of the target proteins and OGT DNA into
expression vectors, transformation of the vectors into expression cells, protein
expression and purification. Once the protein has been successfully produced with and
without the modification, their 3D structures will be determined and compared. E. coli
requires sources of carbon and nitrogen to synthesize proteins. Growing E. coli with
15

N-ammonium chloride and 13C-glucose produces proteins with isotopically labeled

backbones and side chains. This method also allows the isotopic labeling of the OGlcNAc modification.
1. 13 Molecular cloning and gene expression
Molecular cloning is a process where DNA encoding a target protein is inserted
into a cloning vector. This process is usually achieved through polymerase chain
reaction (PCR), restriction digestion, and ligation (Figure 1-7). PCR is an experiment
where a small fragment of DNA is amplified, creating many copies of that fragment.
PCR consist of 3 steps. First, the DNA is denatured separating it into single strands.
Primers anneal, or bind, to their consensus sequences at the 3’ end, and elongation
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occurs. During elongation, RNA polymerase uses DNA base pair components to extend
the primers, which makes a new double stranded DNA fragment. Every time this
process occurs, the DNA fragments double. Once the fragment has been amplified, it is
then digested with restriction enzymes. Restriction enzymes recognize specific DNA
sequences and cleave them, leaving sticky or overlapping ends. This same digestion is
done on the cloning vector. In the ligation step, the sticky ends are bound together by a
ligase. The two pieces of DNA come together to form a plasmid, circular DNA, which is
then transformed into competent E. coli cells. These cells make several copies of the
plasmid that is used for protein expression.
1. 14 Recombinant protein expression and purification
Recombinant protein expression is a process in which DNA corresponding to a
target protein is expressed from a vector. The expression vector is made of DNA that
has all the necessary promoters and operators for protein expression in a bacterial host.
The cloned and recombined DNA is transformed into E. coli and isopropyl β-D-1thiogalactopyranoside (IPTG) is used to induce expression of the protein. The cells are
harvested and lysed through mechanical or chemical force. Soluble proteins are
separated from the cell debris by centrifugation. The protein of interest is isolated
through a purification process such as affinity chromatography. Affinity chromatography
is a process were a protein is tagged with the addition of some sequence of amino acids
that has a moderate binding affinity for a compound immobilized on some type of resin.
For example, nickel affinity chromatography uses the affinity between 6 histidine
residues on the protein and Ni2+ bound to the resin to select for the protein of interest.
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Figure 1-7 Steps involved in molecular cloning. http://cnx. org/contents/185cbf87-c72e48f5-b51e-f14f21b5eabd@9. 45:88/Biology
1. 15 Co-expression of target proteins with OGT
O-GlcNAc transferase (OGT) is the enzyme that adds O-GlcNAc to a target
protein. Scientists began to question if a co-expression of OGT and a target protein
would produce O-GlcNAc-modified protein. Although the mechanism of OGT is not fully
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understood, we know that UDP-GlcNAc is the substrate for the addition of the OGlcNAc modification. E. coli produces UDP-GlcNAc within the cells, making the
expression of O-GlcNAc-modified proteins possible in a co-expression system. David
Vocadlo has expressed a few O-GlcNAc-modified proteins using this method [24].
Expressing the modified protein in E. coli permits 15N and 13C isotopic labeling of the
protein, as well as the modification, for NMR structural analysis.
1. 16 NMR
NMR is an analytical technique where the nuclear spins of a molecule are
aligned by a constant magnetic field. An external oscillating magnetic field generated by
a radiofrequency pulse is used to transfer a population of nuclei into a higher energy
state with phase coherence. As the nuclei relax back to their lower energy state, the
oscillating magnetic field generated by the coherent spins is detected. To date, there is
no protein structure with the O-GlcNAc modification available by NMR or X-ray
crystallography. One of the major setbacks of X-ray crystallography is that the technique
depends on the protein’s ability to be crystallized. It also only gives a static view of a
protein’s structure. NMR allows for the detection of conformational changes under
physiological conditions. Although NMR is limited by the size of proteins that can be
analyzed (about 30 kDa), it is not a problem for this research because all target proteins
are within the applicable size range.
Methods for determination of protein structure by NMR have become standard,
starting with backbone and side chain peak assignment, followed by distance and
restraint measurements, and concluding with the final calculation of the structure. 1H15

N heteronuclear single quantum coherence spectroscopy (HSQC) is the first NMR
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experiment performed on the purified isotopically labeled protein. This experiment gives
one peak for each amide group from each amino acid in the protein. 2D experiments
show the correlation between two nuclei, in this case the 1H attached to the 15N of the
amide group. Side chains containing amines also appear in 1H-15N HSQC experiments
as well. The dispersion, intensity and number of peaks gives valuable information about
the protein sample. Spectra with narrow dispersion between 7-8 ppm indicate that the
protein is unfolded or aggregated. Peak intensity is related to the concentration of the
sample and the oligomerization state. Optimal sample conditions yield greater than 95%
of expected backbone peaks. Once the conditions are optimized, additional experiments
are done for further assignments. The next experiment collected is CBCANH. This 3D
experiment shows which Cα’s and Cβ’s are connected to each amide group previously
identified from the 1H -15N HSQC experiment (Figure 1-8). In most cases, there are two
Cα’s and two Cβ’s peaks for each amide, the Cα/Cβ pair on the previous residue and
the Cα/Cβ pair directly connected to the amide. These Cα/Cβ pairs are indicated by the
residue number i and i -1. Because the i-1 Cα/Cβ pair is not always visible, an additional
experiment is done. CBCA(CO)NH only shows peaks corresponding to Cα/Cβ i-1.
These experiments allow scientists to identify the amino acid backbone peaks of the
protein. Chemical shifts give information about the identity of the side chains and further
experiments can be done if required.
The next set of experiments performed gives information about the secondary
structure by measuring scalar coupling (J-coupling). J-coupling is a through bond
measurement that gives information about bond angles. Nuclear overhauser effects
(NOEs) are through space measurements and give information about protein
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conformation. NOEs between neighboring residues also give secondary structural
information. 2D Nuclear overhauser spectroscopy (NOESY) is used to measure
distances between protons in close proximity. 15N-NOESY experiments give NOE
measurements for all hydrogens within 5 Å of an NH group. 13C-NOESY measures all
the hydrogens within 5 Å of a CH group. Once the NOESY experiments are completed,
there are automated programs that assign the peaks. These assignments, along with
the previous assignments and distance restraints, are used to calculate a protein
structure [40].

Figure 1-8 CBCANH experiment. http://www. protein-nmr. org.
uk/pictures/experiment_types/cbcanh. pngc
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Chapter 2: E. coli sabotages the in vivo production of O-linked-Nacetylglucosamine (O-GlcNAc) modified proteins
2. 1 Introduction
cAMP response element binding protein (CREB1) is a transpiration factor, that
plays a major role in the nervous system and brain. CREB1 is present in both neurons
and glial cells, which are the major components of the nervous system. CREB1 is well
known for its essential role in long-term memory and learning [41]. CREB1 is a human
protein that contains 341 amino acids divided into 4 domains. It includes 2 hydrophobic
and glutamine rich domains: Q1 at the N-terminus and Q2 in the middle of the
sequence. A kinase-inducible domain, KID, separates the Q1 and Q2 domains. The
bZip, basic leucine zipper, domain is at the C-terminus. CREB1 binds to DNA and
activates expression of proteins that contribute to synaptic plasticity [42]. Synaptic
plasticity refers to the process by which synapses are modified in structure and function
in response to different stimuli or environmental cues. Activity-dependent synaptic
plasticity is thought to be the underlying process of learning and memory [43]. Josselyn
et al. showed the first direct evidence that increasing CREB1 levels in a defined
mammalian brain region enhances long-term memory formation [44].
CREB1 is O-GlcNAcylated in vivo. The modification occurs at two residues
between amino acids 256-261 in the Q2 domain at S 1er-260, Thr-256, Thr-259, or Thr261 [41]. Transcriptional activity is repressed when CREB1 is modified with O-GlcNAc
because O-GlcNAc it inhibits CREB1’s association with the coactivator, TATA-
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This chapter previously appeared as: Octavia Y. Goodwin, Maggie S. Thomasson, Aaron J. Lin, Michelle
M. Sweeney, Megan A. Macnaughtan. E. coli sabotage the in vivo production of O-linked-β-Nacetylglucosamine-modified proteins. Journal of Biotechnology 168 (2013) 315-323.
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associated factor (TAFII130) [41].

Figure 2-1The O-GlcNAc modification of CREB1 disrupts binding with TAFII130.
Recent studies have shown that inhibition of O-GlcNAcylation leads to enhanced axonal
and dendritic growth and long-term memory [18]. A study done in mice showed that
mice expressing O-GlcNAcylated CREB1 had a decrease in long-term memory
compared to mice that expressed non-glycosylated CREB1 . In this chapter I describe
how CREB1 was cloned, expressed, and glycosylated in vivo for structural analysis.
2. 2 Materials and methods
2. 2. 1 Materials
Ovalbumin, hen egg white lysozyme, N-acetylglucosaminidase from Canavalia
ensiformis (Jackbean), fluorescein-conjugated wheat-germ agglutinin (FITC-WGA),
glycerol, maleic acid, O-(2-acetamido-2-dexoyd-glucopyranosylidene)amino-Nphenylcarbamate (PUGNAc), 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), sodium
chloride (NaCl), sodium phosphate dibasic, sodium phosphate monobasic,
bromophenol blue, dimethylformamide, 4-methylumbelliferyl-N-acetylglucosaminide
(MU-GlcNAc), sodium carbonate, p-nitrophenyl-β-N-acetylglucosamine (pNP-GlcNAc),
Coomassie brilliant blue R250, sodium dodecyl sulfate (SDS), glycine,
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tris(hydroxymethyl)aminomethane (tris), 2-mercaptoethanol, His-Select Ni-affinity gel,
imidazole, urea, acetic acid, methanol, and kanamycin were purchased from SigmaAldrich. pET-28b vector, Rosetta(DE3) cells, Tuner(DE3) cells, BugBuster protein
extraction reagent, and ampicillin were purchased from EMD Millipore/Novagen. A UNO
S1 cation exchange column, Precision Plus Protein Unstained Standards, 4–20% miniPROTEAN TGX precast gels, immun-blot low fluorescence PVDF membrane, and
Laemmli buffer were purchased from Bio-Rad. 2-log DNA ladder, 10-beta cells, Taq 5X
master mix, T4 DNA ligase, NdeI restriction enzyme, and XhoI restriction enzyme were
purchased from New England Biolabs. BioReagents EZ-Run Rec Protein Ladder, antiO-GlcNAc MAb CTD 110. 6, and DyLight 550-conjugate Goat anti-Mouse IgG
secondary antibody were purchased from Thermo Scientific/Pierce Antibodies. Luria
broth (LB) and agar were purchased from BD Biosciences. Artic Express(DE3) cells and
BL21-Gold(DE3) cells were purchased from Agilent Technologies, Strategene Products
Division. OverExpress C41(DE3) cells and OverExpress C43(DE3) cells were
purchased from Lucigen. Other chemicals and materials used include a glycopeptide
(SVES(β-O-GlcNAc)GSADAK-NH2, Sussex Research), deuterated water (D2O,
Cambridge Isotope Laboratories), isopropyl-D-1-thiogalactopyranoside (IPTG,
Affymetrix Anatrace), primers (Integrated DNA Technologies), a TSKgel G3000 SWxl
gel filtration column (Tosoh Bioscience LLC), full-length cDNA sequence of human
cAMP responsive element-binding protein in pCMV-Sport 6 vector (CREB1, Invitrogen),
QIAprep spin miniprep kit (Qiagen), Costar 96 well UV transparent flat bottom plates, 4
mm susceptibility matched NMR tube (D2O-matched, Shigemi Inc. ), K-12 nagZ
knockout strain (JW1093-1) and K-12 parent strain (BW25113) (Keio Collection, E. coli
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Genetic Resources at Yale, CGSC, The Coli Genetic Stock Center) [45], and clone
HsCD00331895 of the F-actin binding domain of Abelson tyrosine-kinase 2 (ABL2FABD) in pET15 vector (DNASU Plasmid Repository, PSI:Biology-Materials Repository)
[46]. All water used was supplied from a Millipore Direct-Q 3 ultrapure water system.

2. 2. 2 Cloning and expression vectors
The human O-GlcNAc transferase (OGT) was expressed using the pET-43. 1
Ek/LIC vector with the full-length sequence provided by Dr. John Hanover [47]. The
pET-43. 1 Ek/LIC-OGT includes an N-terminal NusA-, 6XHis-, and S-tags. The
sequence of three substrate protein domains were cloned into the expression vector,
pET-28b, with an N-terminal 6XHis tag: the second glutamine-rich domain, Q2, of
human cAMP responsive element-binding protein (CREB1-Q2, amino acids 160–283),
the Q2 and bZIP domains of CREB1 (CREB1-Q2-bZIP, amino acids 160–341), and the
F-actin binding domain of Abelson tyrosine-kinase 2 (ABL2-FABD). CREB1-Q2 and
CREB1-Q2-bZIP were cloned from cDNA of the full-length sequence using PCR primers
and the restriction enzymes NdeI and XhoI. The forward primer used was 5’TACGTCCATATGACTTCAGCACCTGCCATC-3’, and the reverse primer for CREB1Q2 was 5’-TAGCTGCTCGAGTCATGCTGCTTCTTCAGCAGG-3’ and for CREB1-Q2bZIP was 5’-TAGCTGGCGGCCGCTCAATCTGATTTGTGGCAGTA-3’. ABL2-FABD
was cloned from a pET-15 vector (clone HsCD00331895, PSI:Biology-Materials
Repository) using restriction enzymes, NdeI and XhoI. The pET-43. 1 Ek/LIC-OGT,
pET-28b-CREB1-Q2, pET-28b-CREB1-Q2-bZIP, and pET-28b-ABL2FABD were each
transformed into 10-beta E. coli cloning cells. Each plasmid was purified from a 5 mL
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culture and sequenced (GeneLab DNA sequencing service at Louisiana State
University).

2. 2. 3 E. coli cultures and protein co-expression
BL21-Gold(DE3) E. coli competent cells were transformed with pET-43. 1-OGT
and a substrate vector (either pET-28b-CREB1-Q2, pET-28b-CREB1-Q2-bZIP, or pET28b-ABL2-FABD), and selected on agar plates supplemented with ampicillin and
kanamycin. The expression strains were each grown in LB media at 37 °C. At an optical
density at 600 nm of 0. 6–0. 8, the culture was induced with 0. 5 mM IPTG and grown at
37 °C for 3 h, unless otherwise stated. The cells were harvested using BugBuster
protein extraction reagent and French press and/or ultrasonication followed by
centrifugation at 30,000 g for 30 min at 4 °C. For some experiments, OGT and the
substrate proteins were purified using His-Select Ni-affinity gel media using gravity flow.
Cleared lysate was loaded onto 1 mL of Ni-affinity media equilibrated with 50 mM
sodium phosphate, 300 mM NaCl, pH 8. 0 buffer. The media was washed with 20 mL of
buffer with 10 mM imidazole, and the protein was eluted with 10 mL of buffer with 300
mM imidazole. Having 6XHis-tags on both OGT and the substrate proteins allows for
simultaneous purification and evaluation of protein expression levels using SDS-PAGE.
OGT (∼170 kDa) and the substrate proteins (<25 kDa) can be separated using gel
filtration chromatography if needed, or alternatively, OGT can be cloned without the
6XHis tag. Separation of OGT and the substrate proteins was not necessary for the
experiments presented in this chapter.
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BL21-Gold(DE3) E. coli with empty pET28b vector, K-12 parent E. coli, and K-12

∆nagZ E. coli were each grown in 250 mL of LB media at 37 °C. At an optical density at
600 nm of 0. 6, 1. 0 mM IPTG was added to the BL21-Gold(DE3) culture only and all
cultures were incubated for 3 h at 37 °C. The cells from each culture were harvested at
3000 g for 10 min, suspended in 12 mL of Bugbuster protein extraction reagent, and
lysed using French press. Cleared lysate was prepared by centrifugation at 30,000 g for
30 min.

2. 2. 4 O-GlcNAc detection and quantification
SDS-PAGE gels and blots were used to determine the relative amount of OGlcNAc-modified protein compared to total protein. Samples of cleared lysate and
insoluble pellet were prepared for SDS-PAGE in Laemmli buffer with 5% v/v 2mercaptoethanol and incubated at 95 °C for 15 min. The samples were loaded into a 4–
20% gel and run at 125 V for 60 min in 25 mM tris, 192 mM glycine, 0. 1% SDS, pH 8. 3
buffer. Protein ladder was run on each gel, and duplicate gels were run when blot
analysis was needed. The gel was stained with Coomassie Brilliant Blue R250 solution
(0. 1% R250, 50% methanol, 40% water, 10% acetic acid), de-stained (50% water, 40%
methanol, 10% acetic acid), and imaged using a GE Typhoon 9410 imager or Fotodyne
Apprentice system. The contrast and brightness of the images were adjusted using
Microsoft Powerpoint software or ImageJ software to improve the quality of the images
for publication [48].
Blotting methods included both lectin and western blots. Fluorescein-conjugated
wheat-germ agglutinin was used for the lectin blots. Anti-O-GlcNAc MAb CTD 110. 6
and DyLight 550 conjugate Goat anti-Mouse IgG secondary antibody were used for the

26

western blots. Hen egg white lysozyme and ovalbumin were used as positive controls
for the western blots and lectin blots, respectively. All blots were imaged using the GE
Typhoon 9410 imager in the Louisiana State University AgCenter Biotechnology
Laboratory, Protein Facility. ImageJ software was used to measure the band densities
from the Coomassie-stained SDS-PAGE gels (relative total protein concentration) and
from the blots (relative O-GlcNAc-modified protein concentration) [48]. The background
signal was subtracted and the ratios of the blot to gel densities were calculated. The
error calculated from multiple background measurements was propagated and is
represented as error bars.
2. 2. 5 Partial purification of E. coli β-N-acetylglucosaminidase
E. coli β-N-acetylglucosaminidase was partially purified from the cleared lysate of
BL21-Gold(DE3) expressing empty pET-28b, K-12 parent, and K-12 ∆nagZ cultures
using cation exchange chromatography (CXC). A BioLogic DuoFlow 10 system with UV
detection and a fraction collector was used for all chromatography experiments. Cleared
lysate (12 mL) was separated using a UNO S1 cation exchange column into 1 mL
fractions using a buffer gradient of 20 mM sodium phosphate pH 7. 0, from 0 to 0. 5 M
NaCl. The fractions were analyzed for β-N-acetylglucosaminidase activity using the MUGlcNAc fluorescent well-plate assay described in Section 2. 6. The active fractions from
the cleared lysate of BL21-Gold(DE3) expressing empty pET-28b were combined and
used to determine enzyme kinetics and activity toward a glycopeptide. The K-12 parent
and K-12 ∆nagZ fractions were used to test for other β-N-acetylglucosaminidase activity
toward MU-GlcNAc. The cleared lysate from the K-12 ∆nagZ culture was used to test
for other β-N-acetylglucosaminidase activity toward a glycopeptide.
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2. 2. 6 E. coli β-N-acetylglucosaminidase detection assays
Spectrophotometric and fluorescence well-plate methods were used to measure
β-N-acetylglucosaminidase activity. A solution of a chromophoric, β-Nacetylglucosaminidase substrate, pNP-GlcNAc, was prepared in 50 mM tris-maleate,
20% glycerol, pH 7. 7 at 1. 0 mg/mL (2. 9 mM) and preheated to 37 °C. In a 96
wellplate, 20 µL of sample (cleared lysate or chromatography fraction) was added to 90
µL of the pNP-GlcNAc solution (final concentration was 2. 4 mM) and incubated at 37
°C for 30 min. The reaction was quenched with 200 µL of 42 mg/mL (396 mM) sodium
carbonate, which stopped the reaction and converted any cleaved p-nitrophenol to
yellow nitrophenolate. The absorbance at 405 nm was measured with a Biotek
PowerWave XS microplate spectrophotometer and converted to nmoles of
nitrophenolate formed per mL of fraction/min using an extinction coefficient of 18,100 Mcm-1 for nitrophenolate [49]. An assay blank was run with 20 µL of buffer (lysis buffer or
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chromatography buffer) in place of the sample; and, a sample blank was run with 90 µL
of tris-maleate buffer in place of substrate. Each sample and blank were run in triplicate
where indicated. For triplicate measurements, the average absorbance and standard
deviation for each sample and blank were calculated. Detection of β-Nacetylglucosaminidase activity in the chromatography fractions were done by Maggie
Thomasson.
For the fluorescent β-N-acetylglucosaminidase activity assay, a stock solution of
4-methylumbelliferyl-β-N-acetylglucosaminide, MU-GlcNAc, was prepared at 25 mM in
dimethylformamide. A working solution of 1. 5 mM MU-GlcNAc for well plate assays
was made by diluting the stock solution in 100 mM sodium phosphate buffer, pH 7. 4.
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The working solution was preheated to 37 °C. For the 96 well-plate assay, 20 µL of
sample (cleared lysate or chromatography fraction) was added to 90 µL of the MUGlcNAc working solution (final MU-GlcNAc concentration was 1. 2 mM) and incubated
at 37 °C for 30 min. The fluorescence intensity was measured with an excitation
wavelength of 372 nm and emission wavelength of 445nm using a Perkin Elmer Wallac
Victor2 V fluorescence plate reader, housed in the Louisiana State University AgCenter
Biotechnology Laboratory, Protein Facility. A positive control was run using 1 µL of β-Nacetylglucosaminidase from C. ensiformis (Jack bean) in 19 µL of buffer (lysis buffer or
chromatography buffer) with 90 µL of the working MU-GlcNAc solution. A negative
control was run using 20 µL of buffer (lysis buffer or chromatography buffer) with 90 µL
of the working MU-GlcNAc solution. Each sample and blank were run in triplicate where
indicated. For triplicate measurements, the average fluorescence intensity and standard
deviation for each sample and blank were calculated. This fluorescent assay was done
by Maggie Thomasson.

2. 2. 7 Kinetic assays
The Michaelis–Menten constants (Km) for MU-GlcNAc and pNP-GlcNAc and the
inhibition constant (Ki) for PUGNAc were determined for the E. coli β-Nacetylglucosaminidase using the pooled β-N-acetylglucosaminidase-active CXC
fractions (see Section 2. 5). For the pNP-GlcNAc reactions, three replicate samples of
0, 0. 05, 0. 5, 5 mM pNP-GlcNAc and 80 µL of active CXC fraction were mixed in 50
mM sodium phosphate, 500 mM sodium chloride, pH 7. 1 to a final volume of 100 µL. In
addition to the sample blank (0 mM pNP-GlcNAc), an assay blank was made in triplicate
with 5 mM pNP-GlcNAc in buffer. The samples were incubated at 37 °C. One set of the
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triplicate samples was quenched with 200 µL of 396 mM sodium carbonate at 10, 15,
and 20 min. The formation of product was measured as described in Section 2. 6.
The Km for MU-GlcNAc and the Ki for PUGNAc were determined using sets of
three replicate samples at 0, 13. 6, 16. 4, 20. 4, 27. 3, 40. 9, and 81. 8 µM MU-GlcNAc
with 0, 200, and 500 nM PUGNAc. Each sample volume was 110 µL with 20 µL of
active CXC fraction and 100 mM sodium phosphate, pH 7. 4 buffer. The fluorescence
intensities of the samples were measured at room temperature after 4, 9, and 14 min
using a fluorescence plate reader as described in Section 2. 6. The kinetics assay was
done by Maggie Thomasson.

2. 2. 8 Kinetic analysis
Initial velocities (V) at each substrate (S) concentration were determined using
least squares fitting to a linear function, and the average values were calculated for
triplicate measurements. The data were then analyzed by nonlinear regression analysis
using the computer programs of Cleland (1979). Initial velocities were fit to Eq. (1) to
determine the maximal velocity (Vmax) and the Michaelis–Menten constant (Km).

Eq. (1)
Data for competitive inhibition were fit to Eq. (2), where I is the concentration of
PUGNAc and Ki is the inhibition constant. The kinetics analysis was done by Maggie
Thomasson.
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Eq. (2)
2. 2. 9 Inhibition of E. coli β-N-acetylglucosaminidase activity
Cleared lysate from a BL21-Gold(DE3) culture was tested for β-Nacetylglucosaminidase activity using the pNP-GlcNAc spectrophotometric assay
described in Section 2. 6. PUGNAc was added to 20 µL of lysate at varying
concentrations (0, 1, and 2 µM PUGNAc) and mixed with 90 µL of 1. 0 mg/mL pNPGlcNAc. Conditions, blanks, and measurements are the same as described in Section
2. 6.
Changes in the relative amount of O-GlcNAc-ABL2-FABD were measured for coexpression cultures grown with 0, 1, 2, and 10 µM PUGNAc. PUGNAc was added to the
growth media of BL21-Gold(DE3) cells co-expressing pET43. 1 Ek/LIC-OGT and
pET28b-ABL2-FABD. The cultures were grown, harvested, and lysed as described in
Section 2. 3. The soluble and insoluble proteins from each culture were analyzed with
SDS-PAGE and western blot as described in Section 2. 4. The relative amount of OGlcNAc was measured as described in Section 2. 4.
2. 2. 10 NMR experiments to detect E. coli β-N-acetylglucosaminidase hydrolysis
of an O-GlcNAc-modified peptide
To evaluate the activity of the E. coli β-N-acetylglucosaminidase toward protein
O-GlcNAc, a synthetic O-GlcNAc-modified peptide (SVES(β-O-GlcNAc)GSADAK-NH2)
was incubated with partially purified, E. coli β-N-acetylglucosaminidase and K-12 ∆nagZ
lysate. Each reaction mixture was analyzed with 1H NMR to observe the 1H anomeric
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signal of any released α-GlcNAc (5. 2 ppm). This signal was chosen because it has
relatively little background interference. The reaction mixtures contained 200 µM
glycopeptide, 100 µL of β-N-acetylglucosaminidase-active CXC fraction or K-12 ∆nagZ
lysate, 50 mM sodium phosphate, 500 mM NaCl, pH 7. 1 buffer, 10% D2O, and trace
DSS (to lock and reference the NMR signal, respectively).
A glycopeptide control, sample control, and sample control with 200 µM Nacetylglucosamine (GlcNAc) were prepared with 100 µL of CXC buffer instead of active
fraction or lysate, 3. 0 µL of water instead of glycopeptide stock solution, and 1. 3 µL of
20 mM GlcNAc plus 2. 7 µL of water instead of glycopeptide stock solution, respectively.
The samples were either incubated at 37 °C for 5 h (CXC β-N-acetylglucosaminidaseactive fraction) or 22. 5 h (K-12 ∆nagZ lysate). The glycopeptide control and sample
controls were treated with the same conditions. The reactions were performed one time.
The reaction mixtures and controls were analyzed in 4 mm D2O-susceptibility matched
tubes. 1H NMR spectra of the samples were collected on a 700 MHz Varian NMR
equipped with a 5 mm HCN probe. The spectra were collected at 20 °C with
presaturation of water (1 s saturation time, 12 dB saturation power), 1 s acquisition time,
1 s recycle delay, 7000 Hz spectral width, 30 dB gain, and 2048 scans. Data
processing, line broadening (1 Hz exponential), chemical shift referencing, baseline
correction, peak height measurements, and signal-to-noise calculations were performed
with VnmrJ 3. 2 software (Agilent). The amount of released GlcNAc was estimated by
comparing the peak intensities at 5. 198 ppm (left peak of the anomeric 1H α-GlcNAc
doublet) of the reaction mixture to the control sample with 200 µM GlcNAc. For the
glycopeptide reaction with K-12 ∆nagZ lysate, the limit of quantitation (S/N = 10) was
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calculated using the S/N of the 1H anomeric α-GlcNAc peak in the control sample with
200 µM GlcNAc.
2. 3 Results and discussion
2. 3. 1 Co-expression of OGT with substrate proteins using E. coli
The second glutamine-rich domain of human CREB1 (CREB1-Q2) and the Q2
and bZIP domains of CREB1 (CREB1-Q2-bZIP) were co-expressed with full-length
human OGT in BL21-Gold(DE3) E. coli. Even though these vectors have the same
origin of replication, the different antibiotic resistance prevents incompatibility [50]. The
CREB1-Q2 and CREB1-Q2-bZIP domains were chosen as substrate proteins because
the Q2 domain is natively modified with at least two O-GlcNAc molecules that suppress
CREB1-activated transcription [17]. The co-expression cultures were lysed and
separated into soluble lysate and insoluble pellet fractions. The soluble lysate and pellet
were analyzed with Coomassie SDS-PAGE and lectin blot. The results for the coexpression of OGT with CREB1-Q2 and CREB1-Q2-bZIP are shown in Figures 2-2 and
2-3, respectively. Figures 2-2a and 2-3a show the SDS-PAGE gel images for Ni-affinity
purified CREB1-Q2 and CREB1-Q2-bZIP soluble lysate. CREB1-Q2 is highly expressed
and soluble, while CREB1-Q2-bZIP is mainly found in the pellet. The additional bands in
the Ni-affinity purified lysate in Figure 2-2a are E. coli background proteins and 6XHistagged OGT (with multiple translational truncations due to rare codons). Figures 2-2b
and 2-3b show the lectin blots corresponding to the SDS-PAGE gels. The dark bands
indicate where FITC-WGA bound O-GlcNAc-modified proteins. The presence of OGlcNAc was also confirmed with an anti-O-GlcNAc MAb CTD 110. 6 western blot of Niaffinity purified protein from the expression of CREB1-Q2-bZIP (pET-28b-CREB1-Q2-
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bZIP) without and with co-expression of OGT (pET-43. 1-OGT) in E. coli BL21Gold(DE3) (see Supplementary Figure 1). In both lectin blots (Figures 2-2 and 2-3), only
insoluble CREB1-Q2 and CREB1-Q2-bZIP were modified with O-GlcNAc.
The absence of soluble, O-GlcNAc-modified protein from the co-expression
system was unexpected. Others have shown that E. coli co-expression of OGT with
substrate protein produce O-GlcNAc-modified proteins in vivo, but the solubility of the
modified proteins was not specifically addressed in these studies [51-53].

Figure 2-2 The Ni-affinity purified soluble lysate and pellet from co-expression of
CREB1-Q2 (pET-28b-CREB1-Q2) and OGT (pET-43. 1-OGT) in E. coli BL21Gold(DE3) analyzed with (a) Coomassie-stained SDS-PAGE and (b) FITC-WGA lectin
blot detecting O-GlcNAc. The bands corresponding to CREB1-Q2 are indicated with
asterisks.

34

Figure 2-3 The soluble lysate and pellet from co-expression of CREB1-Q2-bZIP
(pET28b-CREB1-Q2-bZIP) and OGT (pET-43. 1-OGT) in E. coli BL21-Gold(DE3)
analyzed with (a) Coomassie-stained SDS-PAGE and (b) FITC-WGA lectin blot
detecting O-GlcNAc. The bands corresponding to CREB1-Q2-bZIP are indicated with
asterisks.
From Figure 2-3a, CREB1-Q2-bZIP shows little soluble protein in the SDS-PAGE
image, so observing only O-GlcNAc-modified CREB1-Q2-bZIP in the pellet is not
informative. However, the solubility of the CREB1-Q2 domain is good, but the OGlcNAc-modified protein only occurs in the pellet. To improve the solubility of the OGlcNAc-modified proteins, the co-expression of OGT with CREB1-Q2 and CREB1-Q2bZIP was tested using additional E. coli expression strains at various conditions.
Rosetta, C41, and C43 E. coli strains were induced with 0. 5 mM IPTG and grown at 37
°C for 3 h and 18 °C for 16 h. The Tuner E. coli strain was grown at the same
temperatures but with 0. 25 mM–1 mM IPTG. Arctic express E. coli cells were induced
with 0. 5 mM IPTG and grown at 4 °C and 12 °C for 24 h. Regardless of the type of E.
coli expression strain or conditions used, the O-GlcNAc-modified CREB1-Q2-bZIP and
CREB1-Q2 proteins were only found in the pellet (data not shown).
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To circumvent the possibility that O-GlcNAc-modified CREB1-Q2 and CREB1Q2-bZIP are inherently insoluble, the F-actin binding domain of Abelson tyrosine-kinase
2 (ABL2-FABD, also known as ARG, Abelson-related gene protein) was selected as a
third test protein. ABL2-FABD was selected because it expresses in high yield with high
solubility in E. coli, actin-binding proteins have been shown to be regulated by OGlcNAc, and ABL2-FABD is predicted to have two sites of O-GlcNAc modification [5457].

Figure 2-4 ABL2-FABD (pET-28b-ABL2-FABD) and OGT (pET-43. 1-OGT) were coexpressed in E. coli BL21-Gold(DE3) with increasing concentrations of PUGNAc in the
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growth media (0, 1, 2, and 10 µM PUGNAc). The soluble lysate (S) and pellet (P) from
each culture was analyzed with (a) Coomassie-stained SDS-PAGE and (b) anti-OGlcNAc MAb CTD 110. 6 western blot. HEWL was used as a positive control in the last
lane. (c) A plot of the relative band density of the western blot band to the Coomassiestained SDS-PAGE gel band (indicated with an asterisk). For each band in (a) and (b),
the background density was measured thrice, subtracted from each band, and used to
estimate the propagated measurement error (represented as error bars in (c)).
Figure 2-4a (Lanes 2 and 3) shows an SDS-PAGE image of the soluble lysate
and pellet from ABL2-FABD co-expressed with OGT. The ABL2-FABD protein is
abundant in both the lysate and pellet, but the western blot image in Figure 2-4b (Lanes
2 and 3) shows small amounts of O-GlcNAc-modified ABL2-FABD only in the pellet.
The absence of soluble O-GlcNAc-modified protein from the co-expression system
suggests two possibilities: (1) the modification causes the proteins to precipitate and/or
(2) the O-GlcNAc modification is being cleaved by an endogenous E. coli enzyme in the
cytoplasm. The second possibility assumes that the insoluble, O-GlcNAc-modified
proteins are protected from the suspected E. coli β-N-acetylglucosaminidase activity.
2. 3. 2 Inhibiting NagZ activity in E. coli increases in vivo O-GlcNAc modification
NagZ, the only E. coli β-N-acetylglucosaminidase identified, is suspected to be
the enzyme that deglycosylates soluble O-GlcNAc-modified protein from the coexpression system. The existence of an O-GlcNAc transferase in E. coli has been ruled
out but the E. coli β-N-acetylglucosaminidase, NagZ, has not been tested for activity
toward O-GlcNAc-modified peptides or proteins [58]. NagZ was first purified from K-12
E. coli and characterized using pNP-GlcNAc in a spectrophotometric assay [59]. The
soluble, cytoplasmic enzyme was found to specifically cleave O-β-linked GlcNAc. Later
characterization of K-12 NagZ demonstrated its role in peptidoglycan recycling by
cleaving the GlcNAc-(1,4)-MurNAc bond (MurNAc, N-acetylmuramic acid) with a Km of
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35 µM for the anhydro-disaccharide [60, 61]. A null mutant showed that NagZ was not
essential to E. coli growth and morphology and was the only E. coli β-Nacetylglucosaminidase [59, 60]. It is possible that NagZ has activity toward O-GlcNAcmodified proteins because it is similar to human O-GlcNAcase (OGA) in substrate (pNPGlcNAc) and inhibitor (PUGNAc). Human OGA cleaves pNP-GlcNAc and is inhibited by
PUGNAc [62, 63]. K-12 NagZ, which has 99% amino acid identity to BL21-Gold(DE3)
NagZ, has a pNP-GlcNAc Km of 0. 31–0. 43 mM [59, 61]. PUGNAc is a potent inhibitor
of Vibrio cholerae NagZ (Ki = 48 nM), a homolog of E. coli NagZ with 56% amino acid
sequence identity [64]. Following the hypothesis that NagZ cleaves O-GlcNAc from
modified proteins in the co-expression system, PUGNAc was tested as an inhibitor of
the enzyme in vitro and in vivo.
The MU-GlcNAc Km and the PUGNAc Ki of BL21-Gold(DE3) E. coli β-Nacetylglucosaminidase were determined using partially purified β-Nacetylglucosaminidase from BL21-Gold(DE3) lysate. β-N-Acetylglucosaminidase-active
CXC fractions were identified with the MU-GlcNAc well-plate assay and pooled together
(Supplementary Figure 2). The MU-GlcNAc Km and the PUGNAc Ki were determined by
measuring the formation rate of 4-methylumbelliferone with a fluorescence plate reader
at varying MU-GlcNAc and PUGNAc concentrations. The data shown in Figure 2-5 were
globally fit to competitive, noncompetitive, and uncompetitive inhibition models using
nonlinear regression analysis, and the competitive model gave the best fit. This result is
expected since PUGNAc is a competitive inhibitor of other β-N-acetylglucosaminidases
and has been shown to bind at V. cholerae NagZ’s active site [62, 64, 65]. The best fit
to Eqs. (1) and (2) give a Km of 5. 6 ± 1. 2 µM MU-GlcNAc and a Ki of 25. 5 ± 4. 6 nM
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PUGNAc. These results are similar to the Km of K-12 NagZ (35 µM anhydrodisaccharide) and the Ki of V. cholerae NagZ (Ki = 48 nM PUGNAc), respectively [61,
64].
Even though PUGNAc is a strong inhibitor of partially purified E. coli β-Nacetylglucosaminidase, the effectiveness of the inhibitor is reduced in cleared lysate.
The E. coli β-N-acetylglucosaminidase activity in cleared lysate was tested with the
addition of 0, 1, and 2 µM PUGNAc.

Figure 2-5 The initial velocities of E. coli β-N-acetylglucosaminidase, partially purified
with CXC from BL21-Gold(DE3) cleared lysate, at varying MU-GlcNAc concentrations
and with different concentrations of PUGNAc. The points represent the observed
velocities, and the lines represent the best fits of the data to Eqs. (1) and (2).
The results of this assay (Figure 2-6) show that PUGNAc inhibits the β-Nacetylglucosaminidase activity, but not as well as expected for a Ki of 25. 5 nM. To rule
out the possibility that E. coli β-N-acetylglucosaminidase has a low pNP-GlcNAc Km, the
Km was measured using partially purified β-N-acetylglucosaminidase from BL21Gold(DE3) lysate. The best fit of the data (Supplementary Figure 3) to Eq. (1) results in
a Km of 0. 35 ± 0. 05 mM, which is within the range of reported values for K-12 NagZ (0.
31–0. 43 mM) and does not explain the reduced effectiveness of PUGNAc in the
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cleared lysate [59, 61]. Another E. coli β-N-acetylglucosaminidase with activity for pNPGlcNAc could also explain these results, but this hypothesis is ruled-out by the lack of
activity of the null mutant (Section 3. 4) and by work published previously [60]. Another
possibility is that the effective concentration of PUGNAc is reduced in the lysate
compared to the CXC active fraction; other enzymes or cellular material in the lysate
may sequester or degrade PUGNAc.
To assess whether inhibition of the E. coli β-N-acetylglucosaminidase increases
the amount of O-GlcNAc-modified ABL2-FABD produced with the co-expression
system, PUGNAc was added to the growth media at 0, 1, 2, and 10 µM. The relative
amount of O-GlcNAc-modified ABL2-FABD produced was determined by normalizing
the western blot band density to total ABL2-FABD protein using the band density of a
duplicate SDS-PAGE gel image (Figure 2-4a and b). As shown Figure 2-4c, the amount
of insoluble, O-GlcNAc-modified ABL2-FABD increases with increasing PUGNAc,
consistent with an E. coli β-N-acetylglucosaminidase cleaving O-GlcNAc in vivo. Even
with 10 µM PUGNAc, soluble O-GlcNAc-modified ABL2-FABD is absent (Figure 2-4b).
This result is consistent with poor inhibition of E. coli β-N-acetylglucosaminidase in the
cleared lysate with PUGNAc. The possible explanations are the same as discussed in
the previous paragraph with the additional possibility of inefficient transport into the cell.
Alternatively, the results suggest that soluble, O-GlcNAc-modified ABL2-FABD is
unstable. However, the latter is not supported by the fact that the relative levels of
soluble to insoluble ABL2-FABD (as assessed by SDS-PAGE (Figure 2-4a)) are not
significantly different even when O-GlcNAc is increased. These results taken together
indicate that an E. coli enzyme, likely NagZ, cleaves O-GlcNAc from the soluble protein,
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the enzyme is inhibited by PUGNAc, the effectiveness of PUGNAc inhibition in cleared
lysate and in vivo is reduced, and the insoluble O-GlcNAc-modified ABL2-FABD is
protected from the β-N-acetylglucosaminidase activity.

Figure 2-6 The β-N-acetylglucosaminidase activity of cleared lysate with PUGNAc (0, 1,
2 µM) was measured using the pNP-GlcNAc spectrophotometric assay. The lysate was
from the co-expression of ABL2-FABD (pET-28b-ABL2-FABD) and OGT (pET43. 1OGT) in E. coli BL21-Gold(DE3). Each sample and control were run in triplicate, and the
error bars represent the standard deviation of these measurements. The 405 nm
absorbance values were converted to activity (right vertical axis) using the extinction
coefficient of nitrophenolate.
2. 3. 3 E. coli NagZ cleaves O-GlcNAc from a peptide
To determine if E. coli β-N-acetylglucosaminidase can deglycosylate an OGlcNAc-modified peptide, the release of GlcNAc from a synthetic O-GlcNAc-modified
peptide incubated with partially purified E. coli β-N-acetylglucosaminidase was
monitored with 1H NMR. The α-GlcNAc anomeric 1H signal at 5. 2ppm (Figure 2-7, full
spectra in Supplementary Figure 4) was monitored for the glycopeptide control, the
glycopeptide and active fraction mixture, the active fraction control, and the active
fraction control with 200 µM GlcNAc after incubation at 37 °C for 5 h. No α-GlcNAc was
detected in the glycopeptide or active fraction control samples (Figure 2-7a and d). αGlcNAc was detected in the mixture of glycopeptide and partially purified β-Nacetylglucosaminidase sample (Figure 2-7c) at a concentration of approximately 40 µM
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GlcNAc. These results demonstrate that the E. coli β-N-acetylglucosaminidase has
activity toward this O-GlcNAc-modified peptide, and likely has activity toward O-GlcNAcmodified proteins in vivo.

Figure 2-7 Fractions from CXC of BL21-Gold(DE3) lysate with β-Nacetylglucosaminidase activity toward MU-GlcNAc were pooled and tested for β-Nacetylglucosaminidase activity toward the synthetic O-GlcNAc-modified peptide,
SVES(β-O-GlcNAc)GSADAK-NH2. (a) CXC fraction control, (b) CXC fraction control
with 200 µM GlcNAc added, (c) CXC fraction with 200 µM glycopeptide, and (d) 200 µM
glycopeptide control in CXC buffer. The spectra shown are expanded regions from 5. 1
to 5. 3 ppm, with a gray dashed line indicating the α-GlcNAc chemical shift (center of
the doublet). All spectra were processed and expanded identically for direct
comparison. The full spectra are included in Supplementary Figure 4. The glycopeptide
control sample (d) has extra noise due to truncation artifacts from the water peak; the
additional noise is small and does not affect spectral interpretation. Based on the 1H
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anomeric α-GlcNAc intensity in (b), approximately 40 µM GlcNAc was hydrolyzed by the
E. coli β-N-acetylglucosaminidase in 5 h at 37 °C (c).
2. 3. 4 Identifying the E. coli β-N-acetylglucosaminidase as NagZ
To verify that NagZ is the only β-N-acetylglucosaminidase in E. coli and the
enzyme purified and characterized in these studies, a K-12 ∆nagZ strain and parent
strain were tested for β-N-acetylglucosaminidase activity. Cleared lysate from cultures
were tested for activity using the MU-GlcNAc fluorescence assay (Supplementary
Figure 5). As expected, activity was detected in the K-12 parent strain. No significant
activity was found in any of the fractions or the cleared lysate of the K-12 ∆nagZ strain,
indicating that NagZ is the only β-N-acetylglucosaminidase in E. coli, as Yem and Wu
also observed [59]. These results confirm that the β-N-acetylglucosaminidase-active
fractions used in the kinetic assays and NMR experiments must have contained NagZ.
To determine if NagZ is the only E. coli enzyme with activity toward O-GlcNAcmodified proteins, lysate from K-12 ∆nagZ strain was incubated with 200 µM O-GlcNAcmodified peptide and monitored with 1H NMR. Even after 22. 5 h of incubation at 37 °C,
the 1H spectrum (Figure 2-8c, full spectra in Supplementary Figure 6) did not show any
detectable α-GlcNAc greater than the limit of quantitation (10 µM). The lack of activity
toward the glycopeptide indicates that NagZ is the one and only enzyme that sabotages
the in vivo production of O-linked β-N-acetylglucosamine-modified proteins with E. coli.
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Figure 2-8 1H NMR spectra of (a) ∆nagZ K12 lysate, (b) lysate with 200 µM GlcNAc,
and (c) lysate with 200 µM glycopeptide, SVES(β-O-GlcNAc)GSADAK-NH2. All samples
were incubated at 37 °C for 22. 5 h to test for β-N-acetylglucosaminidase activity toward
the synthetic O-GlcNAc-modified peptide. The spectra shown are expanded regions
from 5. 1 to 5. 3 ppm, with a gray dashed line indicating the α-GlcNAc chemical shift
(center of the doublet). All spectra were processed and expanded identically for direct
comparison. The full spectra are included in Supplementary Figure 6. Based on the
signal-to-noise ratio of the 200 µM GlcNAc peak in (b), the limit of quantitation (LOQ) in
(c) is 10 µM GlcNAc.
2. 4 Conclusions
E. coli has not been used to produce milligram quantities of soluble O-GlcNAcmodified proteins because an endogenous E. coli enzyme, NagZ, removes O-GlcNAc
from modified proteins in vivo and in vitro. An E. coli co-expression system was
developed to modify proteins with O-GlcNAc in vivo using human OGT. E. coli is a good
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host because it lacks endogenous OGT activity, can produce milligram quantities of
protein, and allows for metabolic labeling with isotopes for NMR structure determination.
Three substrate proteins were successfully O-GlcNAc-modified with the co-expression
system: CREB-Q2, CREB-Q2-bZIP, and ABL2-FABD. CREB-Q2 and ABL2-FABD, in
particular, are soluble proteins, but the O-GlcNAc-modified proteins were only found in
the insoluble pellet. The O-GlcNAc-modification may cause the substrate proteins to
become unstable and precipitate; particularly, if the modification is added cotranslationally before the protein has folded. Independent of whether O-GlcNAc causes
insolubility, several pieces of evidence suggest that E. coli NagZ cleaves O-GlcNAc
from the soluble substrate protein in vivo and in vitro. The amount of O-GlcNAcmodified ABL2-FABD produced with the co-expression system increased when a β-Nacetylglucosaminidase inhibitor, PUGNAc, was added to the growth media. NMR was
used to show that an E. coli enzyme cleaves O-GlcNAc from an O-GlcNAc-modified
peptide, a foreign substrate. Even though the E. coli β-N-acetylglucosaminidase was not
directly identified with mass spectrometry, the lack of β-N-acetylglucosaminidase activity
in lysate from a K-12 ∆nagZ strain both toward MU-GlcNAc and an O-GlcNAc-modified
peptide demonstrates that NagZ is the only E. coli β-N-acetylglucosaminidase.
Moreover, the lack of activity in the knockout confirms that NagZ was present in the
samples shown to cleave O-GlcNAc and is inhibited by PUGNAc. The Km’s of
BL21Gold(DE3) NagZ determined, 0. 35 mM pNP-GlcNAc and 5. 6 µM MU-GlcNAc, are
consistent with values published for K-12 NagZ [59, 61]. The inhibition constant of
BL21-Gold(DE3) NagZ was determined to be 25. 5 nM and is consistent with V.
cholerae NagZ, but the mechanism of reduced PUGNAc effectiveness in cleared lysate
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and in in vivo experiments remains unclear [64]. Efforts are currently underway to test
the co-expression system in ∆nagZ E. coli strains for increased yields and soluble OGlcNAc-modified proteins.
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Chapter 3: Is NagZ the saboteur?
Chapter 3. 1 Introduction
3. 1. 1 The Hexosamine biosynthesis pathway in E. coli
UDP-GlcNAc is an important component in E. coli. It is a major precursor of the
bacterial cell wall. (3) The enzymes of the hexosamine biosynthesis pathway in E. coli
are different from those in humans, but the steps of the pathway are similar. Glucose is
transported into the E. coli cell and phosphorylated by a glucose specific
phosphotransferase (PstG), and phospho-glucose isomerase (Pgi) interconverts
glucose-6-phosphate to fructose-6-phospate. Glucosamine-6-phosphate synthase
(GlmS) transfers an amino group from glutamine to make glucosamine-6-phosphate,
which is then converted to glucosamine-1-phosphate by phosphoglucosamine mutase
(GlmM). N-acetylglucosamine-1-phosphate is formed through the acetylation of
glucosamine-1-phosphate by glucosamine-1-phosphate acetyltransferase (GlmU).
Finally, N-acetylglucosamine-1-phosphate is uridylated by N-acetylglucosamine-1phosphate uridylyltransferase (GlmU) to form uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc). Glucosamine and N-acetylglucosamine can enter the HBP as well.
Glucosamine is transported into the cell and phosphorylated by mannose transporter
(ManXYZ), and N-acetylglucosamine is transported and phosphorylated by NagE, a Nacetylglucosamine specific transporter. N-acetylglucosamine is deacetylated by Naceytglucosamine-6-phosphate deacetylase to glucosamine-6-phosphate where it
continues along the HBP [66, 67]. N-acetylglucosamine that is cleaved from the cell wall
by NagZ is phosphorylated by NagK and used to make more UDP-GlcNAc [68].
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Figure 3-1 Glucose, glucosamine, and N-acetylglucosamine are used by E. coli’s
hexosamine biosynthesis pathway to make UDP-GlcNAc.

3. 1. 2 The role of β-N-acetylglucosaminidase (NagZ) in E. coli
E. coli is a prokaryotic single cell organism with a cellular membrane made of
murein also known as peptidoglycan. Peptidoglycan is composed of cross-linked
alternating GlcNAc-β1,4-MurNAc-peptide monomers [68]. The main function of the
peptidoglycan layer is to support the cell wall structure and balance the cytoplasm’s
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osmotic pressure. There are several enzymes that participate in the degradation of the
peptidoglycan layer. NagZ is the only β-N-acetylglucosaminidase whose function is to
cleave N-acetylglucosamine (GlcNAc) from N-acetylmuramic acid (MurNAc) peptides
for peptidoglycan recycling [69].

Figure 3-2 NagZ cleaves the bond between GlcNAc and MurNAc, of the peptidoglycan
layer [70]. Adapted from: Triassi, A. J. , M. S. Wheatley, M. Savka, H. M. Gan, R. C. J.
Dobson, and A. O. B. Hudson, L,l-diaminopimelate aminotransferase (dapl): A putative
target for the development of narrow-spectrum antibacterial compounds. Frontiers in
Microbiology, 2014. 5.
GlcNAc, clea:ved from the cell, is recycled to make more UDP-GlcNAc, which is
a precursor used to make the peptidoglycan. Knocking out nagZ inhibits the cells ability
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to cleave GlcNAc from MurNAc leading to a build-up of the disaccharide in the
cytoplasm. nagZ knockout (ΔnagZ) cells have less GlcNAc and UDP-GlcNAc in the
cytoplasm compared to the wild type [69]. The level of O-GlcNAcylation is dependent
upon the amount of UDP-GlcNAc [71]. Although a ∆nagZ system for expression of OGlcNAc-modified proteins may prevent glycosidase activity, it may be limited in the
amount of glycoprotein it can produce because of the lower level of UDP-GlcNAc. In this
chapter we will analyze the effects of ΔnagZ on the expression of O-GlcNAc-modified
proteins.
3. 2 Materials and Methods
3. 2. 1 Materials
Hen egg white lysozyme, glycerol, glucose (Glc), glucosamine (GlcN), N-acetylD-glucosamine (GlcNAc), O-(2-acetamido-2-dexoy-d-glucopyranosylidene)amino-Nphenylcarbamate (PUGNAc), sodium lauroyl sarcosinate (sarkosyl), sodium chloride
(NaCl), sodium phosphate dibasic, sodium phosphate monobasic, 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), bromophenol blue, Coomassie brilliant blue
R250, sodium dodecyl sulfate (SDS), glycine, tris(hydroxymethyl)aminomethane (tris),
2-mercaptoethanol, imidazole, urea, acetic acid, methanol, and kanamycin were
purchased from Sigma-Aldrich. Rosetta(DE3)pLysS cells, BugBuster protein extraction
reagent, and ampicillin were purchased from EMD Millipore/Novagen. A UNO S1 cation
exchange column, Precision Plus Protein Unstained Standards, 4–20% mini-PROTEAN
TGX precast gels, immun-blot low fluorescence PVDF membrane, and Laemmli buffer
were purchased from Bio-Rad. 2-log DNA ladder, 10-beta cells, T4 DNA ligase, NdeI
restriction enzyme, and XhoI restriction enzyme were purchased from New England
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Biolabs. BioReagents EZ-Run Rec Protein Ladder, Coomassie (Bradford) Protein Assay
kit, O-GlcNAc-modified BSA, anti-O-GlcNAc MAb CTD 110. 6, and DyLight 550conjugate Goat anti-Mouse IgG secondary antibody were purchased from Thermo
Scientific/Pierce Antibodies. Luria broth (LB) and agar were purchased from BD
Biosciences. Wheat germ agglutinin (WGA) agarose and O-GlcNAc-modified BSA were
purchased from Vector Labs. Other chemicals and materials used include isopropyl βD-1-thiogalactopyranoside (IPTG, Affymetrix Anatrace), Ni Sepharose 6 Fast flow (GE
Healthcare), chloramphenicol (Calbiochem), QIAprep spin miniprep kit (Qiagen), Costar
96 well UV transparent flat bottom plates, K-12 ∆nagZ knockout strain (JW1093-1) and
K-12 parent strain (BW25113) (Keio Collection, E. coli Genetic Resources at Yale,
CGSC, The Coli Genetic Stock Center) [72], and clone HsCD00331895 of the F-actin
binding domain of Abelson tyrosine-kinase 2 (ABL2-FABD) in pET15 vector (DNASU
Plasmid Repository, PSI:Biology-Materials Repository) [46]. All water used was supplied
from a Millipore Direct-Q 3 ultrapure water system.

3. 2. 2 Knocking out the nagZ gene in the Rosetta(DE3) pLysS strain
The ∆nagZ Rosetta(DE3)pLysS strain was made by Dr. William Doerrler and Lisa
Boughner, a graduate student.
3. 2. 3 Making the ΔnagZ Rosetta(DE3) pLysS cells competent
Four single ∆nagZ Rosetta(DE3)pLysS colonies were cultured in 5 mL of LB with
kanamycin (50 µg/ml) and chloramphenicol (35 µg/ml) at 37 oC overnight. These
cultures were added to 50 mL of fresh LB with the appropriate antibiotics and cultured
for 3 hr. The cells were cooled on ice for 20 min and spun down at 3,000 g for 15 min at
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4 oC. The cells were resuspended in 10 mL of 0. 1 M CaCl2 at 4 oC and spun down
again. The supernatant was removed and the cells were allowed to dry for 1 min. The
cells were reconstituted in 2 mL of 0. 1 M CaCl2 at 4 oC and stored as 100 µl aliquots for
transformation.

3. 2. 4 Transformation
pCDF-ABL2 and pET43. 1-OGT were transformed into the ΔnagZ
Rosetta(DE3)pLysS competent cells using a heat shock method. A mixture of 1 µl of
each plasmid and 100 µl of the competent cells was heat shocked at 42 oC for 45 s. The
cells were immediately chilled on ice for 2 min and incubated with shaking for 1 hr at 37
C. ΔnagZ Rosetta(DE3)pLysS colonies with pCDF-ABL2 and pET43. 1-OGT were
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grown on LB agar with 50 µg/mL spectinomycin, 100 µg/mL ampicillin, 50 µg/mL
kanamycin, and 35 µg/mL chloramphenicol.

3. 2. 5 Expression conditions
ABL2 and OGT were co-expressed in ΔnagZ Rosetta(DE3)pLysS cells. Three
colonies of ΔnagZ Rosetta(DE3)pLysS with pCDF-ABL2 and pET43. 1-OGT were
cultured overnight at 37 oC in 150 mL of LB with the appropriate antibiotics. 1 mL of the
overnight culture was used to inoculate fresh LB or minimal media (see Table 3-1 for
minimal media expression recipe) with the appropriate antibodies at 37 oC. Once the
cultures reached an OD600 of 0. 6-0. 8, they were divided into three 50 mL aliquots and
induced with 50 µL of 0. 5 M IPTG. Each 50 mL aliquot was incubated at 16 oC, 23 oC,
and 37 oC for 16 hr, 12 hr, and 3 hr, respectively. The cells were harvested by
centrifugation at 3000 g for 15 min at 4 oC. The supernatant was discarded, and the
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pellet was reconstituted with 1 mL of BugBuster. The suspended cells were sonicated
using a Sonics Vibra-cell VCX130 at 30% power for 120 s (3 cycles of 30 s on/10 s off).
The lysed cells were spun down at 30,000 g for 30 min at 4 oC. The cleared lysate was
separated from the pellet and saved for nickel affinity chromatography. The expression
procedure was performed for pCDF-ABL and pETDuet-1-codon optimized OGT coexpression in ΔnagZ Rosetta(DE3)pLysS.
Table 3-1 The recipe for 1 L of minimal growth media, 1 L of 10X M9 salts, and 100 mL
of 1000X trace mineral.
10X M9 salts

100. 0 ml

D-glucose stock (20 g/100 ml) (0. 2 µm filter sterilized)

20. 0 ml

1000X Trace minerals

1. 0 ml

1 M MgCl2 (autoclaved)

2. 0 ml

50 mM CaCl2 (autoclaved)

2. 0 ml

Vitamin Solution (1 tablet/20 ml) (0. 2 µm filter sterilized)

2 ml

10X M9 salts (autoclaved)
Na2HPO4•7H2O

128 g

KH2PO4

30 g

NaCl

5g

NH4Cl

10g

1000X Trace Minerals (10 mM each) (autoclaved)
FeCl3•6H2O

0. 2703 g

CuSO4•5H2O

0. 2497 g

MnSO4•6H2O

0. 1690 g

ZnSO4•6H2O

0. 2875 g
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3. 2. 6 Ni-affinity purification conditions
Ni Sepharose 6 Fast Flow with a binding capacity of 40 mg/mL was used in 0. 1
mL aliquots. The nickel media was placed in microspin columns and centrifuged at 300
g to remove the storage buffer. Water was used to rinse the media, followed by 1 mL of
wash buffer (50 mM phosphate, 150 mM NaCl, and 20 mM imidazole at pH 8) to
equilibrate the media. The cleared lysate was added to the equilibrated media and
allowed to flow through by gravity. The media was washed with 2 mL of wash buffer.
The protein of interest was eluted using 200 µL of elution buffer (50 mM phosphate, 150
mM NaCl, and 300 mM imidazole at pH 8).

3. 2. 7 SDS-PAGE and western blot analysis
The cleared lysate and insoluble pellet were analyzed with SDS-PAGE and
western blot analysis. The cleared lysate was diluted in a 1:5 ratio with BugBuster or
SDS-PAGE buffer. 20 μL of the dilute cleared lysate was added to 20 μL of Laemmli
sample buffer. The samples were divided in half to run on two different gels. Purified
samples were prepared as 30 μL aliquots in a 1:1 ratio with Laemmli buffer. These
samples were also divided for two different gels: one gel was stained with Coomassie
brilliant blue R-250 stain, and the other gel was prepared for O-GlcNAc detection by
western blot analysis. All samples were boiled for 15 min before loaded onto a 4-20%
tris protein gel. The protein gels were run in buffer (25 mM tris, 192 mM glycine, and 0.
1% SDS) at 120 V for 1 hr.
Western blot detection of O-GlcNAc was performed by transferring the proteins
from the gel to a PVDF-membrane in transfer buffer (25 mM tris, 192 mM glycine, and
10% methanol) using a Bio-Rad transfer electrophoresis system at 120 V for 3 hr. Anti-
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O-GlcNAc MAb CTD 110. 6, an O-GlcNAc specific antibody, in combination with
DyLight 550-conjugate Goat anti-Mouse IgG, a secondary antibody conjugated to a
fluorescent tag, was used to probe the blot for detection of O-GlcNAc. The membranes
were first blocked using 1X BSA blocking buffer (25 mM sodium phosphate,150 mM
NaCl, 0. 1% tween and 1% BSA at pH 7. 4) for 1 hr at room temperature. Anti-OGlcNAc antibody and fresh BSA blocking buffer in a 1:5000 dilution were added to the
blot and incubated at room temperature for 1 hr. The blot was rinsed with PBST buffer
(25 mM sodium phosphate, 150 mM NaCl, and 0. 1% tween at pH 7. 4) three times for 5
min each. The secondary antibody was added to fresh 1X BSA blocking buffer and
incubated at room temperature for an additional hour. The blot was rinsed a final time
and imaged using a GE Typhoon 9410 imager. The fluorescent secondary antibody was
excited at 532 nm and detected between 565-595 nm using a 580 nm filter.

3. 2. 8 WGA agarose affinity chromatography
The nickel purified samples were exchanged into WGA wash buffer (20 mM
HEPES, 150 mM NaCl at pH 8) using Amicon centrifugal filter units with a molecular
weight cut-off of 10 kDa to remove the imidazole. The WGA agarose was divided into
100 µL aliquots and washed with 1 mL of wash buffer. The sample was incubated with
the WGA agarose for 20 hr at 4 oC. The mixture was then transferred to a microspin
column and centrifuged at 300 g for 1 min. The agarose was washed with 1 mL of wash
buffer, incubated with 200 µL of WGA elution buffer (20 mM HEPES, 150 mM NaCl, 500
mM GlcNAc at pH 8) for 30 min at 4 oC, and centrifuged again to collect the elution.
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3. 2. 9 Coomassie protein concentration assay
Nickel-purified and WGA-separated samples were exchanged into WGA wash
buffer using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa.
Aliquots (10 µL) aliquots were saved for Coomassie analysis. BSA standards were
prepared in WGA wash buffer at 0, 10, 20, 40, 50 μg/mL. Standards and samples were
prepared in 50 μL aliquots. Samples were tested and prepared within the linear range
based on visual inspection. The flow-through and eluents from the WGA purification
were analyzed using a Biotek PowerWave XS microplate spectrophotometer at 595 nm.
3. 2. 10 Supplementing ∆nagZ E. coli cultures with sugar
pCDF-ABL2 and pET43. 1-OGT were transformed into ∆nagZ
Rosetta(DE3)pLysS competent cells and selected on LB agar with spectinomycin,
ampicillin, kanamycin, and chloramphenicol, as previously described. A colony known to
express ABL2 and OGT well was cultured in MM in the presence 0. 5% glucose,
glucosamine, or N-acetylglucosamine in addition to the 0. 4% glucose already in the
MM. At an optical density at 600 nm of 0. 6-0. 8, the cultures were induced with 0. 5 mM
IPTG and grown for 16 hr at 22-25 oC. The cells were harvested using BugBuster
protein extraction reagent and lysed with 3 freeze/thaw cycles and ultrasonication.
Cleared lysate was prepared by centrifugation at 30,000 g for 30 min at 4 oC. Ni
Sepharose 6 Fast Flow, a nickel affinity media, was used to purify the His-tagged ABL2
protein. Gravity flow was used to ensure maximum binding. The nickel affinity media
was equilibrated with wash buffer. The cleared lysate was loaded onto 200 µL of media.
The media was then washed with 2 mL of buffer and the protein was eluted with 1 mL of
300 mM imidazole elution buffer.
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3. 2. 11 Resolubilized O-GlcNAc-modified ABL2
The insoluble portion of the cell lysates were dissolved in 1 mL of 10% sodium
lauroyl sarcosinate (sarkosyl), followed by dilution to 1% sarkosyl with water and
ultrasonication at 30% for 120 s (3 cycles of 30 s on/10 s off). The resolubilized protein
was centrifuged at 30,000 g for 30 min to pellet any remaining insoluble material and
purified using nickel affinity chromatography as previously described.

3. 2. 12 OGT activity assay
ΔnagZ Rosetta(DE3)pLysS with pCDF-ABL2 and pET43. 1-OGT and ΔnagZ
Rosetta(DE3)pLysS with pCDF-ABL2 with pETDuet-1-codon optimized OGT were
expressed for 3 hr at 37 oC. The cells were spun down at 3000 g for 10 min at 4 oC. The
cells were resuspended in 50 mM tris and ultrasonicated at 30% for 120 s (3 cycles of
30 s on/10 s off). The lysate was separated from the cells by centrifuging at 30,000 g for
10 min. 1 mM UDP-GlcNAc, 2 μM phenylmethylsulfonyl fluoride (PMSF), 75 units of
shrimp alkaline phosphatase, and 12. 5 mM magnesium chloride were added to the
lysates and incubated at 20 oC for 1 hr. The mixtures were analyzed by SDS-PAGE and
western blot to determine the relative activity of OGT and codon-optimized OGT. In
addition to O-GlcNAc detection, OGT was detected using Anti-O-GlcNAc Transferase
(DM-17) produced in rabbits and DyLight 650-conjugate Goat anti-Rabbit IgG.
3. 3 Results
3. 3. 1 Expression of O-GlcNAc-modified ABL2 in ΔnagZ E. coli
pET43. 1-OGT and pCDF-ABL2 were co-expressed in ΔnagZ
Rosetta(DE3)pLysS using LB media at 16 oC. Figure 3-3a shows the SDS-PAGE of the
soluble purified ABL2 at a molecular weight of about 14 kDa. Once purified proteins
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began to precipitate. The precipitated proteins were also analyzed by SDS-PAGE,
Figure 3-3a shows the precipitated protein, referred to as insoluble. ABL2 purified at pH
6 did not produce precipitate or ABL2. Figure 3-3b shows the western blot
corresponding to these samples. The O-GlcNAc-modified ABL2 was only in the
insoluble sample.
ABL2 was expressed in abundance, but the purification was poor and once
purified, it was unstable. The O-GlcNAc-modified ABL2 selectively precipitated with
many other proteins. The instability is attributed to purification at high pH (> than 8. 5).
Even though glycosylated ABL2 was temporarily soluble, the amount of O-GlcNAcmodified protein produced was similar to the wild type expressions. ABL2 was purified
at a lower pH in an attempt to stabilize the glycoprotein. However, lowering the pH to 6
hindered the lysis and purification of ABL2.

Figure 3-3 O-GlcNAc-modified ABL2 expressed in the ∆nagZ system was unstable and
O-GlcNAc-ABL2 selectively precipitated. The soluble and insoluble samples both
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contain ABL2 as seen on the protein gel (a); however, the western blot (b) shows that
O-GlcNAc-modified ABL2 seems to be exclusively in the pellet.
3. 3. 2 ΔnagZ Rosetta(DE3)pLysS sugar trials
pET43. 1-OGT and pCDF-ABL2 were co-expressed in ΔnagZ
Rosetta(DE3)pLysS using minimal media (MM) at 22 oC. Glucose, glucosamine, Nacetylglucosamine or PUGNAc were added to the MM cultures. The soluble lysate and
the insoluble pellets were analyzed by SDS-PAGE and western blot. Figure 3-4a shows
the SDS-PAGE analysis of cleared lysate, where the asterisk indicates the expression
of ABL2. The corresponding western blot (Figure 3-4b) does not show any glycosylation
for the samples with additional sugar. However, there is a small amount of glycoprotein
in the control sample. Figure 3-4c shows the SDS-PAGE analysis of the insoluble pellet.
The western blot (Figure 3-4d) shows an increased amount of glycoprotein in the
glucose and glucosamine supplemented expressions, compared to the control. The
addition of PUGNAc also increased the amount of glycoprotein expressed. However,
ABL2 expressed in the presence of N-acetylglucosamine produced glycoprotein
comparable to the control.
Glucose, glucosamine, and N-acetylglucosamine were added to the culture
media in an attempt to compensate for the possible decrease of UDP-GlcNAc caused
by knocking out nagZ. These monosaccharaides were selected because they
participate in the hexosamine biosynthesis pathway. The cultures were grown in MM to
control the sugar composition and concentration in the media. The soluble lysate and
the insoluble pellets were analyzed by SDS-PAGE and western blot. As previously
observed, little or no glycoprotein was present in the lysate of the cultures (Figure 3-4a).
MM cultures with extra glucose and glucosamine had the highest amount of
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glycosylation observed thus far. In contrast, the addition of N-acetylglucosamine had no
effect on the expression of glycoprotein. The cells with N-acetylglucosamine grew four
times faster than the cultures with the other sugars and minimal media alone. The
accelerated growth and insubstantial change in glycosylation may be attributed to Nacetylglucosamine’s ability to up-regulate nagA and nagB, which promote glycolysis
[73]. Glycolysis is a process where E. coli uses sugars (mainly glucose) to make ATP,
which is required for maintenance and reproduction of the cells [74]. The addition of
PUGNAc also increased the amount of glycosylation, suggesting the presence of a
second glycosidase with activity toward O-GlcNAc-modified proteins in E. coli.

60

Figure 3-4 Analysis of sugar supplemented expression of O-GlcNAc modified ABL2.
The cleared lysate from cultures supplemented with glucose have a small amount of
ABL2 (a) that is not glycosylated (b). The pellets corresponding to these samples
contain about the same amount of ABL2 (c); however, the samples supplemented with
glucose and glucosamine have an abundance of O-GlcNAc-modified ABL2 (d). The
pellets containing PUGNAc express more ABL2 (c), but less O-GlcNAc-modified ABL2
compared to the glucose and glucosamine samples (d).

3. 3. 3 Resolubilized ABL2
The insoluble glycoprotein from Figure 3-4d was solubilized using detergent and
isolated from insoluble content and cell debris using nickel affinity chromatography.
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Figure 3-5a shows the SDS-PAGE analysis of purified resolubilized ABL2. There were
very small amounts of ABL2 and some other proteins observed. The western blot
(Figure 3-5b) shows that these results were similar to previous results. The glucose,
glucosamine, PUGNAc, and PUGNAC+glucose samples had higher levels of
glycosylation than the control and N-acetylglucosamine sample.
The overall goal of this project is to express milligram quantities of soluble OGlcNAc-modified protein for NMR analysis. In an effort to solubilize O-GlcNAc-modified
ABL2 without denaturing the protein, sarkosyl was used to solubilize any protein from
the inclusion bodies. The results were similar to the previous experiments: glucose and
glucosamine appeared to have more glycoprotein than both the control and the Nacetylglucosamine sample. The glucose in combination with PUGNAc appeared to have
the highest level of purified O-GlcNAc-modified ABL2. The asterisks in Figure 3-5b
indicate multiple O-GlcNAc-modified ABL2 bands that migrate differently in the SDSPAGE gel. More than one O-GlcNAc modification can occur on ABL2, so the bands may
correspond to different numbers of O-GlcNAc residues. There are a few proteins that
consistently co-purify with ABL2, suggesting that O-GlcNAc-modified ABL2 may be
bound to or tightly associated with these proteins.
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Figure 3-5 Purification of resolubilized O-GlcNAc-modified ABL2. The pellets were
resolublized with 10% sarkosyl, diluted to 1%, and purified with nickel affinity
chromatography. The results were very similar to previous data—there is not an
abundance of ABL2 on the protein gel, (a) yet it is highly glycosylated (b).

3. 3. 4 Optimized expression of O-GlcNAc-modified ABL2 in ∆nagZ
Previous experiments produced highly glycosylated protein (Figure 3-4d) that
was insoluble. This glycoprotein can be isolated from the pellet using a sarkosyl.
Although the detergent experiments worked, it is not clear whether sarkosyl will affect
the protein’s structure. In an effort to optimize the expression, for the production of
soluble O-GlcNAc-modified ABL2, the cells were cultured in different conditions. There
are many variables that can greatly affect the expression of soluble target protein. The
cells were cultured in a tissue culture flask at slower revolutions per minute (rpm). The
flat tissue flask doubled the surface area of aeration. These expressions were done at
room temperature (22-25 oC) instead of a controlled temperature of 22 oC for 18 hrs.
The expressions were induced with IPTG at an OD600 of 1. 0, instead of 0. 6. Most
importantly, 10 μM PUGNAc was added to all of the purification buffers. The samples
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were purified and concentrated for analysis. The sample with 0. 5% glucose was the
only sample that showed significant amounts of pure, soluble O-GlcNAc-modified
protein (Figure 3-6). Although the overall expression of ABL2 appears to be low, the
ratio of glycoprotein to naked protein was high. In contrast to expression in wild type E.
coli, O-GlcNAc-modified ABL2 expressed in ∆nagZ E. coli remained glycosylated in the
presence of PUGNAc after several days. O-GlcNAc-modified ABL2 expressed in the
wild type, in the presence of 10 μM PUGNAc lost the modification after 2 days. It is not
clear whether the decreased amount of ABL2 is real or if the glycosylation disrupts the
binding of the coomassie G-250 dye, used for detection of protein. Coomassie is also
the reagent used in protein concentration assays, and is not compatible with high levels
of GlcNAc.

Figure 3-6 Optimized expression of soluble O-GlcNAc-modified protein. A starter
culture from a single colony was used to inoculate sugar-supplemented cultures in MM.
The expression conditions were optimized to produce soluble O-GlcNAc-modified
protein. The soluble lysate was purified and concentrated for SDS-PAGE and western
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blot analysis. The glucose sample was the only sample to produce a substantial amount
of soluble O-GlcNAc-modified protein.
3. 3. 5 Comparison of OGT activity produced from human OGT (hOGT) and
codon-optimized OGT (coOGT)
The human OGT sequence contains 52 rare codons. Rare codons are DNA
codons that have a low amount of corresponding tRNA, required for protein synthesis,
in E. coli. The OGT sequence was codon optimized, cloned into pETDuet-1 by the
protein facility at LSU, and overexpress in E. coli. Although codon optimized OGT overexpressed in ∆nagZ E. coli, it did not show any glycosylation, even when glucose and
glucosamine were added as supplements to the media. To verify that the coOGT was
active, cleared lysate containing coOGT was used to glycosylate ABL2 in vitro, and the
relative amount of glycosylation was compared to hOGT in vitro glycosylation. Figure 37 shows the SDS-PAGE and western blot of the in vitro glycosylation reaction. There is
more coOGT than hOGT and there is more O-GlcNAc-modified protein produced from
the hOGT reaction. A comparison of the relative band densities of the western blot
bands to the corresponding SDS-PAGE band for the in vitro coOGT and hOGT
reactions show that the extent of glycosylation is similar for both enzyme. The same
cleared lysate was analyzed to assess the relative concentrations of OGT. coOGT was
more abundant than hOGT. In theory more coOGT should produce more O-GlcNAcmodified protein, but it does not. These results suggest that coOGT is not as active as
hOGT, likely because it does not fold properly during translation.
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Figure 3-7 Comparison of human OGT and codon optimized OGT. Anti-O-GlcNAc
transferase was used to detect the amount of OGT present in the in vitro reaction. AntiO-GlcNAc was used to detect the amount of O-GlcNAc-modified protein produced from
the reaction.
3. 4 Conclusion
The ΔnagZ Rosetta(DE3)pLysS E. coli co-expression system produced more OGlcNAc-modified ABL2 compared to wild type Rosetta(DE3)pLysS E. coli, but only
when the media was supplemented with extra glucose or glucosamine. The insolubility
of O-GlcNAc-modified ABL2 was a problem for both E. coli strains, providing more
evidence that co-translational modification with O-GlcNAc disrupts ABL2 folding.
Another possibility is that a second glycosidase is removing O-GlcNAc from soluble
ABL2. Evidence for this hypothesis includes increased levels of O-GlcNAc-modified
ABL2 when PUGNAc is added to cultures of ΔnagZ Rosetta(DE3)pLysS E. coli coexpressing OGT and ABL2. Since O-GlcNAc-modified ABL2 is available in the pellet,
resolubilized O-GlcNAc-modified ABL2 may be available in sufficient quantities for NMR
analysis. Another possible solution to producing O-GlcNAc-modified protein in sufficient
quantities for NMR analysis is to switch the target protein to one that has been modified
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with in vivo methods. David Vocadlo has had great success with tau and it is biologically
relevant. [24]
In vitro glycosylation could be a viable method to produce mg quantities of OGlcNAc-modified protein. In the past, in vitro glycosylation has not been efficient, but
NagZ may have contributed to this apparent inefficiency. The ∆nagZ E. coli may allow
for in vitro glycosylation without the need for β-N-acetylglucosaminidase inhibitors.
Optimizing the expression of human OGT is also very important. Increasing the amount
of hOGT expressed, while maintaining its activity, should increase the amount of protein
being glycosylated in the lysate. Partial codon optimization may lead a properly folded,
active, and abundant OGT. Rosetta cells contain tRNA for 6 common rare codons.
There are 52 rare codons in the hOGT sequence, Rosetta compensates for all but 10.
These 10 codons are all CGA. Mutating these codons, without changing the amino acid
may lead to more protein expression.
Wheat germ agglutinin is often used to enrich O-GlcNAc-modified proteins, but it
is expensive and is not always efficient because of its weak affinity for terminal GlcNAc.
In a situation where there is only a very small percent of O-GlcNAc-modified protein,
enrichment is important for down-stream analysis like mass spectrometry and NMR.
Galactosyltransferase adds a galactose to O-GlcNAc. This enzymatic process has been
used to detect O-GlcNAc. While the addition of functionalized galactose provides other
ways to analyze the modification. The functionalized galactose has a reactive group that
can be used to bind biotin for enrichment with streptavidin [75]. The addition of a mass
tag, such as polyethylene glycol (PEG) has been used to visualize multiple-O-GlcNAc-
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modified proteins by SDS-PAGE gel and could be used to give valuable information
such as how much of the protein is O-GlcNAc-modified and to what degree [33].
While there is still some optimization required for the co-expression system to
produce mg quantities of soluble O-GlcNAc-modified protein, there are some promising
opportunities that need to be explored. The resolubilized samples are highly
glycosylated and the structures of these proteins should be analyzed. If they are
properly folded, they may lead to an NMR structure. Even with small amounts of
resolubilized O-GlcNAc-modified protein, mass spectrometry can be used to map the OGlcNAc sites to specific residues. This information alone can provide valuable insight
into the role of O-GlcNAc in the structure and function of proteins.
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Chapter 4: Chlamydia trachomatis CT663: Structure and Ligand
Interaction Model
4. 1 Introduction
4. 1. 1 Chlamydia trachomatis
Chlamydia is the most common sexually transmitted bacterial disease in the
United States [76]. There are 2. 8 million new infections annually [77]. Chlamydia can
cause reproductive health complications such as pelvic inflammatory disease, infertility
and ectopic pregnancy. It can also cause neonatal conjunctivitis and pneumonia [78].
The disease is asymptotic in 50-80% of patients, so they are often unaware of the
infection [79]. The rate of re-infection is alarmingly high [80]. Although Chlamydia is both
curable and preventable, there is a need for better therapies. In 2000, three chlamydial
strains in clinical patients demonstrated multi-drug resistance to doxycycline,
azithromycin, and ofloxacin [79].
Chlamydia is an obligate intracellular bacteria, which means it requires a host cell
for replication. It infects columnar epithelial cells, which are found in the uterus, the
respiratory tract, and the eye. The disease manifests in these areas as a urogenital
infection, pneumonia, and conjunctivitis, respectively. The developmental cycle is
unique and consists of two alternating cellular forms. The infectious form, elementary
bodies (EB), attach to host cells and initiate the developmental cycle, after endocytosis
[81]. The EBs develop into the noninfectious replication form called reticulate bodies
(RB). These RBs reorganize in an asynchronous manner and then revert back to EBs.
The now multiplied EBs exit the host cells, lysing the cells in the process [82]. The
newly produced EBs infect new cells and the cycle starts again.

69

Figure 4-1 Developmental cycle of Chlamydia. Brunham, R. C. ; Rey-Ladino, J. ,
"Immunology of Chlamydia infection: Implications for a Chlamydia trachomatis vaccine,"
Nature Reviews Immunology 2005, 5 (2), 149-161.
4. 1. 2 Type III secretion
The elementary bodies use the virulence associated type III secretion system
(T3SS) to infect the host cells. The T3SS is used by gram-negative bacterial pathogens
to deliver virulence factors, molecules essential for the induction of infection, into the
cytosol of host cells [3]. Virulence factors can be a wide variety of molecules, and are
usually on the bacterial surface or secreted from the pathogen. Because the molecules
are critical for the initiation and replication of the disease, they are sensible targets for
drug development [83]. The T3SS is composed of an injectisome, an ATPase,
translocator molecules, effector molecules, and chaperones [84]. The injectisome is the
major machinery of the virulence T3SS. It is a multi-protein complex that consists of a
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basal body embedded within the bacterial membrane topped by a needle-like structure
[85]. It serves as a channel through which proteins reach the host cell. Proteins are
secreted through the injectisome by an ATP consuming process, using ATPases
located in the bacterial cytosol [84]. Translocator proteins are secreted to form the
translocon, which sits at the needle-like end of the injectisome. The translocon
physically links the injectisome to the host cell, enabling secretion of virulence factors
into the host cell.

Figure 4-2 Diagram of animal pathogenic bacterial T3SS similar to that of Chlamydia
[86]. Büttner D , and He S Y Type III Protein secretion in plant pathogenic bacteria.
Plant Physiology. 2009;150:1656-1664.
The secreted virulence factors consist of effector and chaperone proteins.
Effectors are eukaryotic-like proteins that modulate the host cell throughout the
infectious cycle. Bacterial pathogens secrete effectors that manipulate the actin
cytoskeleton of the host cell, which enables remodeling of the membrane in order to
promote uptake or adhesion of the bacteria [84]. Effectors and translocators are often
bound to chaperones in the bacterial cytosol. Chaperones are proteins that bind to
virulence factors in order to keep them in secretion-competent state as they travel from
the bacteria and through the injectisome. The chaperones also prevent aggregation and
premature interaction of virulence factors, as well as regulate transcription of T3SS
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genes [87]. T3SS chaperones can be categorized into three classes based on structure
and substrate similarity. Class I chaperones are approximately 130 residues. Class IA
chaperones associate with only one effector, while those in class IB associate with
multiple effectors. Both sub-classes of class I adopt homo-dimeric structural folds. Class
II chaperones are approximately 160 residues and associate with translocator proteins.
They are structurally distinct, typically containing three tetratricopeptide repeats (TPR)
[84, 88]. Class III chaperones are extra-cellular filament proteins that have extended
alpha helical structure.

4. 1. 3 CT663/Scc1-CopN complex
CT663 is a class 1A chaperone found in Chlamydia trachomatis. It is a dual
function enzyme; it functions as a chaperone and as a transcription factor that regulates
the global transition from RB to EB in the Chlamydial developmental cycle. CT663
carries out this function by associating with the β subunit (RpoB) and the primary sigma
subunit σ66 (RpoD) of Chlamydial RNA polymerase (RNAP). This association inhibits σ66
dependent transcription [89]. Analysis of CT663 as a chaperone has shown that it
interacts with secretion substrates as well as another class IA T3SS chaperone, Scc1
[84]. This interaction suggests that CT663 and Scc1 form a heterodimeric chaperone
complex. The Ct663/Scc1 complex binds Chlamydial outer protein N (CopN), a T3SS
effector that is essential for virulence. CopN destroys microtubules in cytoskeleton
networks, resulting in cell cycle arrest. CopN is also a T3SS plug protein [90]. Plug
proteins typically block the secretion pore, allowing protein export only in the presence
of a currently unknown extracellular signal [84]. Although the formation of a CT663,
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Scc1, and CopN complex has been confirmed, the order of binding events and
arrangement are unknown.

4. 1. 4 Research goal
The goal of this research is to determine the structure and analyze the ligand
interactions of CT663. Analysis of CT663’s interactions with σ66, β-subunit, Scc1, and
CopN will provide information about how CT663 functions as a dual enzyme. Structural
analysis of CT663 and its binding partners will provide a rational drug model.
Knowledge of how these proteins interact will facilitate the design of a small molecule
that inhibits key interactions necessary for infection. An x-ray crystallographic structure
of CT663 has been attempted by David Worthylake, a collaborator at LSU Health
Science Center School of Medicine, but crystal formation has not been successful.
Nuclear magnetic resonance (NMR) spectroscopy will be used to determine the
structure of the chaperones CT663 and Scc1, as well as the chaperone complex
CT663/Scc1. Structural determination of any of the chaperones bound to the effector
CopN is not feasible, due to size constraints. NMR can still provide information about
these interactions, such as which residues participate in binding and how binding affects
the structure of the chaperones. Further binding analysis will be done using surface
plasmon resonance (SPR) spectroscopy to determine the binding kinetics and
arrangement of CT663, Scc1, and CopN.
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4. 2 Materials and Methods
4. 2. 1 Materials
Glycerol, glucose, sodium chloride (NaCl), sodium phosphate dibasic, sodium
phosphate monobasic, 2-(N-morpholino)ethanesulfonic acid (MES), ammonium acetate,
dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), bromophenol blue,
Coomassie brilliant blue R250, sodium dodecyl sulfate (SDS), glycine,
tris(hydroxymethyl)aminomethane (tris), 2-mercaptoethanol, imidazole, urea, acetic
acid, methanol, kanamycin, ampicillin, and chloramphenicol were purchased from
Sigma-Aldrich. Rosetta(DE3)pLysS cells, BugBuster protein extraction reagent, 3K and
10K Amicon centrifugal filters, and ampicillin were purchased from EMD
Millipore/Novagen. Precision Plus Protein Unstained Standards, 4–20% mini-PROTEAN
TGX precast gels, and Laemmli buffer were purchased from Bio-Rad. BioReagents
glutathione agarose, HRV 3C protease, EZ-Run Rec protein ladder, and Coomassie
(Bradford) protein assay kit were purchased from Thermo Scientific/Pierce Antibodies.
Luria broth (LB) and agar were purchased from BD Biosciences. Hiprep 16/60
Sephacryl-S-100 HR and Ni Sepharose 6 Fast flow were purchased from GE
Healthcare. Other chemicals and materials used include isopropyl β-D-1thiogalactopyranoside (IPTG, Affymetrix Anatrace), deuterium oxide (D2O, Cambridge
Isotopes), tween 20 (Fisher), chloramphenicol (calbiochem), QIAprep spin miniprep kit
(Qiagen), Costar 96 well UV transparent flat bottom plates were also purchased.
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4. 2. 2 Structure predictions
The amino acid sequence of CT663, Scc1, and CopN were submitted to an
online protein homology/analogy recognition engine version 2. 0 (Phyre2) for structure
prediction.

4. 2. 3 CT663 expression and purification
pET21-CT663 was transformed into Rosetta (DE3)pLysS competent E. coli cells
and plated on Luria broth (LB) agar with 100 µg/mL ampicillin and 35 µg/mL
chloramphenicol. Single colonies were selected for inoculating 5 mL of LB as starter
cultures and grown overnight at 37 oC with a shaking speed of 250 revolutions per
minute (rpm). The starter culture was added to 0. 5 L of LB media and grown at 37 oC
with 250 rpm. Once the culture reached an OD600 of 0. 6-0. 8, it was induced with 0. 5
mM IPTG. The culture grew at 37 oC for 3 hr and the cells were harvested at 4,000 g for
10 minutes at 4 oC. The cells were reconstituted in 10 mL of BugBuster followed by
ultrasonication at 30% power for 120 s (3 cycles of 30 s on/10 s off) using a Sonics
Vibra-cell VCX130. Cleared lysate was prepared by centrifugation at 30,000 g for 30
min at 4 oC. CT663 was purified from the cleared lysate using 1 mL of Ni Sepharose 6
fast flow media by gravity flow. CT663 was washed with 20 mL of 20 mM sodium
phosphate, 300 mM NaCl, 20 mM imidazole, pH 8 buffer and eluted in 10 mL of buffer
with 300 mM imidazole.

4. 2. 4 CT663 and Scc1 co-expression and co-purification:
E. coli cells containing pACYC184-Scc1-6XHis and pET28-CT663 were sent to
us by our collaborator, Dr. Li Shen, at the LSU Health Science Center School of
Medicine. The cells were plated on LB agar with 35 µg/mL chloramphenicol and 50
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µg/mL kanamycin. 5 mL starter cultures were grown from single colonies. The starter
culture was added to 0. 5 L of LB media at 37 oC. Once the culture reached an optical
density of 0. 6-0. 8 at 600 nm, they were induced with 0. 5 mM IPTG and 0. 2%
arabinose. The cells were harvested and the Scc1:CT663 complex was co-purified
following the same procedures used for CT663 (see section 4. 2. 1).

4. 2. 5 CopN expression and purification
E. coli cells containing pGEX098-CopN were sent to us by our collaborator, Dr. Li
Shen, at the LSU Health Science Center School of Medicine. The cells were plated on
LB agar with 100 µg/mL ampicillin. The cells were grown and harvested following the
same procedures used for CT663 (see section 4. 2. 2). CopN was purified using 1 mL of
glutathione agarose media by gravity flow. The media was equilibrated with 10 mL of 50
mM tris, 150 mM NaCl, pH 8 buffer (TBS). The cleared lysate was added to the media
and gently mixed at 4 oC for 30 min. The media was washed with 20 mL of TBS. The
GST-fusion tag was cleaved from CopN using 20 units of HRV 3C protease in 2 mL of
TBS with gently mixing at 4 oC for 16 hr. The flow-through containing CopN and HRV 3C
was collected, and HRV 3C was removed by passing the sample over 0. 5 mL of nickel
affinity media.

4. 2. 6 Separation of CT663 and Scc1
Previous research indicates that Scc1 is insoluble when expressed alone.
However, when it is co-expressed with CT663, it forms a soluble complex. The
CT663/Scc1 complex was expressed and purified as previously described. 6M urea, 8M
urea, 2% SDS and 1% sarkosyl were used to separate the complex. Fast protein liquid
chromatography (FPLC) was used to bind the complex to nickel media. The media was
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washed with wash buffer containing one of the separating agents. Any remaining bound
protein was eluted with 20 mM sodium phosphate, 300 mM NaCl, and 300 mM
imidazole at pH 8 buffer. The UV absorbance was monitored for the release of protein
during the separation wash. SDS-PAGE was used to analyze the proteins that eluted
after separation.

4. 2. 7 Gel electrophoresis analysis
Purified CT663, Scc1/CT663 complex, and CopN were run in 4-20% tris-HCl gels
under denatured and native conditions. The denatured samples were prepare in a 1:1
ratio with Lammeli buffer containing 5% v/v 2-mercaptoethanol and heated at 95oC for
15 minutes. The samples were ran at 125 V for 60 min in 25 mM Tris, 192 mM glycine,
1. 0% SDS, pH 8. 3 running buffer. Prior to running the native samples the 4-20% trisHCl gel was run in 25 mM tris, 192 mM glycine, pH 8. 3 native running buffer for 60 min
to remove the SDS from the gel. Samples prepared for the native gel were buffer
exchanged into 20 mM tris, 100 mM NaCl, pH 8 buffer and concentrated to 25 µM in 20
µL using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa. Each
sample was run individually along with 1:1 mixtures of CopN:CT663 and
CopN:Scc1/CT663. These mixtures were incubated at 25oC for 1. 5 hr. 10% glycerol
was added to the native sample in a 1:2 ratio and the native gel was fun for 75 min at
125 V.

4. 2. 8 Gel filtration analysis
CT663 and the Scc1/CT663 complex were analyzed with quantitative gel filtration
analysis using either a HiPrep Sephacryl S-100 HR with a 1 mL sample injection volume
or an ENrich 70 SEC column with a 50 µL sample injection volume. Two stock solutions
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of CT663 and two stock solutions of the Scc1/CT663 complex were prepared for
analysis using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa.
The concentrations and buffer conditions of each sample are listed in Table 4-1. Protein
concentrations were determined using the Bradford colorimetric assay with Coomassie
Plus reagent and a Biotek PowerWave XS microplate spectrophotometer. Standard
curves were generated using molecular weight standards (2 mg/mL BSA, 1 mg/mL βlactoglobulin, 1 mg/mL cytochrome C, and 50 mM cytidine) using each running buffer:
(1) 20 mM tris, 150 mM NaCl, pH 8. 0, (2) 20 mM tris, pH 7. 4, (3) 50 mM potassium
phosphate monobasic/sodium phosphate dibasic (K-Na-phosphate), pH 7. 3, and (4) 20
mM sodium acetate, pH 4. 5. Regression analysis was used to determine the linear
relationship between the elution volume and the logarithm of the molecular weight for
each column/buffer combination. The molecular weights of the samples were
determined using the linear function to determine the oligomeric state of the samples in
each buffer.

4. 2. 9 SPR Analysis
Binding experiments were conducted using a kinetic titration method called
single-cycle kinetics. This method consists of serial injections of analyte at increasing
concentrations over the surface of a ligand-functionalized sensor chip surface without
regeneration between sample injections [91]. SPR studies were performed at 25 oC on
a nitrilotriacetic acid (NTA) chip (Xantec) on a BIAcore T100 system (GE Healthcare).
Both cells of the uncharged NTA chip were conditioned with 0. 5 M EDTA at a flow rate
of 10 μL/min with 180 s of contact time, followed by 0. 1 M NaOH at a flow rate of 10
μL/min with 180 s of contact time. Two capture cycles were performed on the second
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cell of the sensor chip to create a capture baseline. The capture cycle included three
steps: charging the surface with Ni2+, capturing the ligand, a series of washes, and
surface regeneration. The second cell of the chip was charged with 5 mM NiCl2 at a flow
rate of 10 μL/min with a contact time of 120 s. Charging the surface with nickel allows
the binding of histidine tagged ligands, such as the His-Scc1/Ct663 complex. The HisScc1/CT663 complex was prepared in running buffer (50 mM potassium phosphate,
150 mM NaCl, 5 mM EDTA, 0. 005 % Tween at pH 7. 3) and immobilized onto the
surface at a flow rate of 10 μL/min with a contact time of 150 s. The chip was
regenerated with 0. 5 M NaOH at a flow rate of 30 μL/min for 2 min, followed by 350 mM
EDTA at 30 μL/min for 2 min. The capture cycle was repeated. The analyte binding step
was a single cycle kinetic method with 5 increasing concentrations. This cycle consisted
of a charging step, a ligand capture step, followed by 5 analyte binding and dissociation
steps. CopN, the analyte, was flown at a rate of 10 μL/min with 150 s of contact time
across the second cell with a dissociation time of 240 s. The parameters of the other
steps were the same. CopN was passed across the surface of the first flow cell as a
control or blank.

4. 2. 10 NMR buffer optimization for CT663
CT663 was expressed in minimal media as previously described (Chapter 3).
Isotopic labeling was incorporated by adding 15NH4Cl to the MM. The proteins were
purified with Ni-affinity chromatography as previously described. Purified CT663 was
purified with size exclusion chromatography using a Hiprep 16/60 Sephacryl-S-100 HR
column in 20 mM PBS at pH 7. 15N-CT663 was concentrated to 500 µM and exchanged
into 20 mM sodium phosphate, 20 mM tris, and 20 mM MES buffers using Amicon
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centrifugal filters units with a molecular weight cut-off of 3 kDa. The samples were
concentrated to a final volume of 250 µL and transferred to 5 mm Shigemi tubes with
10% D2O. An 1H -15N HSQC spectrum of each sample was collected on a Varian 700
MHz NMR.
4. 2. 11 15N-CT663/Scc1 NMR analysis
15

N-CT663 was expressed, purified, exchanged into 20 mM sodium acetate at pH

6 buffer, and concentrated to 500 µM as previously described. pACYC-184-Scc1 was
transformed into BL21 cells and selected on LB agar with 35 µg/mL chloramphenicol. A
single colony was added to 10 mL of LB and grown overnight. This starter culture was
added to a 1L of LB and cultured at 37 oC until it reached an OD600 of 0.6-0.8. The cells
were induced with 0. 5 mM IPTG and cultured at 37 oC for 3 hr. The cells were
harvested by centrifugation at 4000 g for 10 minutes at 4 oC and reconstituted in 10 mL
of 8 M urea in BugBuster. Sonication at 30% power pulsed for 120 s (3 cycles of 30 s
on/10 s off) was used to lyse the cells, and cleared lysate was prepared by
centrifugation at 30,000 g for 30 min at 4 oC. After filtering the cleared lysate with a 0.
22 µM syringe filter. The denatured Scc1 was bound to Sepharose 6 fast flow media
using the FLPC. The media was washed with 10 mL of 20 mM sodium phosphate, 300
mM NaCl, 20 mM imidazole, and 6 M urea at pH 8 buffer. A 30 mL linear gradient at 0.
1 mL/min from 6 M urea to 0 M urea was used to refold the protein on the column.
Refolded Scc1 was eluted with 20 mM sodium phosphate, 300 mM NaCl, and 300 mM
imidazole at pH 8 buffer. Scc1 was exchanged into 20 mM sodium acetate at pH 6
buffer and added to the 15N-CT663 sample. The 1H -15N HSQC spectra of 250 µL of 500
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µM 15N-CT663 before and after the addition of Scc1 were collected on a Varian 700
MHz NMR.
4. 3 Results
4. 3. 1 Structural predictions of the Chlamydial trachomatis T3SS effectorschaperone complex CT663:SCC1:CopN
The T3SS is not exclusive to Chlamydia trachomatis and is used by other
pathogens as well. The T3SS apparatus itself has been shown to display notable
similarities among different bacterial species [92]. E. coli, Yersinia, Salmonella, and
Shigella are a few examples of pathogens that use the T3SS. The macromolecules of
the T3SS are well characterized for these pathogens. High-resolution crystal structures
of all classes of T3SS chaperones, crystal structures of the proteins involved in basal
body formation, and NMR and FTIR analyses of needle proteins have advanced the
structural knowledge of the T3SS [92]. Using the structures of chaperones and effectors
from other bacterial species as a basis has allowed for a structural prediction of
CT663/Scc1 in complex with CopN. Protein homology/analogy recognition engine
version 2. 0 (Phyre2) is a structure prediction server that uses homology/analogy of
known structures to predict the structure of other proteins. Structural homology is based
on two principles: “first, the structure of a protein is determined by it’s amino acid
sequence; second, proteins with similar sequences are practically identical in structure,
and even proteins that have distantly related sequences still fold into similar structures”
[93]. Protein analogy refers to proteins with similar functions despite their different
sequences. The structure of CT663 was predicted with 97% sequence coverage from 4
template structures of T3SS chaperones from other bacteria [94-97]. The structure of
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Scc1 was predicted based on three proteins with 92% coverage [94, 97, 98]. The
structural orientation of CopN in complex with CT663/Scc1 was predicted based on a
Yeseria pestis effector chaperone complex (PDB 1XKP) [99]. The Yeseria pestis
complex as well as a protein from Shigella flexneri was used to predict the structure of
CopN with 92% coverage [99, 100]. The structure prediction was done to better
understand how CT663 forms a complex with SCC1 and CopN.

Figure 4-3 The CopN:CT663:Scc1 structure is modeled using Yersinia pestis virulence
factor YopN in complex with the heterodimeric chaperone SycN-YscB by Phyre2.
4. 3. 2 Expression and Purification
The expression and purification conditions were optimized by Dr. Li Shen, our
collaborator at the LSU Health Science Center School of Medicine. CT663, Scc1/Ct663,
and CopN express with yields of ~5 mg, ~66 mg, and ~2 mg of protein per liter of
culture, respectively. The purification of these proteins is relatively clean. Figure 4-4
shows the SDS-PAGE and native gel analysis of the purified proteins. The SDS-PAGE
gels separate denatured proteins based on their size and charge. While native gels
separate the proteins in the same manner, the proteins are in their native state and SDS
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is not available to bind and add negative charge. Without SDS to denature and add
uniform negative charge, it is hard to determine the exact mass of the native proteins.
However, it appears that CT663 and CT663/Scc1 form dimers under native conditions.
CopN was cloned and expressed with a glutathione S-transferase (GST) fusion tag for
purification. This GST tag forms dimers, so the CopN dimer was expected and not
informative. While Figure 4-4a shows CopN cleaved from GST, the CopN used for the
native gel is not cleaved. A quick and dirty binding assay, mixing proteins in 1:1 ratio,
showed no binding of the chaperones with CopN. This result is inconsistent with gel
filtration analysis and is likely an artifact from interactions with the gel and/or
interference from the GST fusion tag.

Figure 4-4 SDS-PAGE and native PAGE analysis of CT663, Scc1/CT663, and CopN.
The protein molecular weight ladder is shown in lane 1 in the (a) SDS-PAGE and (b)
native PAGE gel images. The molecular weight of CT663, Scc1/Ct663 and CopN are
14. 7 kDa, 30. 9 kDa, and 45. 2 kDa respectively.
4. 3. 3 Separation of CT663/Scc1 complex
The CT663/Scc1 complex is expressed within E. coli as a complex and also copurifies. The fact that CT663 and Scc1 purify together suggests a very low dissociation
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constant. Since Scc1 is difficult to produce when expressed in E. coli alone, we tried to
separate CT663 and Scc1 and recover each protein in a soluble, folded state. The
complex was bound to nickel affinity media through the His-tag on Scc1. Urea was used
to try to separate and elute CT663 from Scc1. 6 and 8 M urea were not sufficient to
destabilize the interaction between the CT663 and Scc1. Urea is a very common
compound used to denature proteins. The exact mechanism of how urea denatures
proteins is not known, but studies have shown that urea disrupts hydrophobic
interactions. Urea also interacts with polar residues and the peptide backbone to
stabilize the denatured form of the protein [101]. The fact that 8 M urea is not enough to
separate CT663 from Scc1 suggests that interactions other than hydrophobic, like
electrostatic and hydrogen bonds, contribute to the stability of the complex.

Figure 4-5 CT663-Scc1 interaction. Purified CT663 and CT663:Scc1 complex are
shown in lanes 2 and 3, respectively. The purified CT663-Scc1 complex was
immobilized on 1 mL of Ni-affinity media via a 6XHis tag on Scc1 and washed with 20
mL of wash buffer with 6 M urea (lane 4), 8 M urea (lane 5), and 2% SDS (lane 6). Even
under strong denaturing conditions of 8 M urea, some CT663 remained bound to 6XHistagged Scc1. SDS (2%) was sufficient to disrupt the CT663:Scc1 interaction, resulting in
pure Scc1.
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4. 3. 4 Buffer dependent gel filtration analysis
Gel filtration was done in an effort to characterize the oligomeric state of the
chaperones CT663 and CT663/Scc1. The goal of this study was to find conditions
where the chaperones were in their monomeric state. CT663 and Scc1 formed a
heterodimer in 20 mM sodium acetate at pH 4. 5, while CT663 formed high order
oligomers regardless of buffer conditions.

Figure 4-6 Gel filtration analysis of CT663 and CT663:Scc1 at various buffer conditions.
Two gel filtration column were used to analyze the samples: (A) a HiPrep Sephacryl S100 HR column using a 1 mL sample volume and (B) an Enrich SEC 70 column using
50 L sample volumes. Molecular weight standards were used to determine the linear
relationship between the elution volume and the logarithm of the molecular weight for
each column/buffer combination. The molecular weight of the samples were determined
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using the best-fit linear function based on regression analysis to determine the
oligomeric state of the samples in each buffer. The sample concentrations were 81-152
µM except for the CT663:Scc1 complex in sodium acetate, which was 27 µM due to its
instability in this buffer. Details about the sample conditions are described in Table 4-1.
(A) In Tris/saline buffer at pH 8. 0, CT663 (solid black line) predominantly exists as
higher order oligomers (>300 kDa) and as a homodimer while the CT663:Scc1 complex
(dashed black line) predominantly forms a stable tetramer. In acetate buffer at pH 4. 5,
CT663 and the CT663:Scc1 complex are unstable. CT663 readily precipitates, but the
complex stability was better and showed that soluble CT663:Scc1 in acetate buffer
(gray solid line) exists as a heterodimer. (B) In phosphate buffer at pH 7. 3 (solid black
line), CT663 forms a homodimer and in Tris buffer at pH 7. 4 (dashed black line), CT663
forms homotrimers.
4. 3. 5 Detergent assisted Gel filtration
Since different buffers and salt did not separate CT663 oligomers, detergents
were added in an attempt to stabilize the monomeric form of CT663. When the
detergents were added to Tris buffer, it increased the aggregation of the protein (Figure
4-6a). The detergents had little effect on CT663 in phosphate buffer, as shown in Figure
4-6b.
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Figure 4-7 Detergent effects on CT663 oligomerization. (A) CT663 samples were run in
20 mM Tris, pH 7. 4 buffer (solid black line) with 1 mM SDS (dotted black line), 10 mM
SDS (dashed black line), and 0. 01% Triton X-100 (dash-dotted black line). The
predicted elution volumes for CT663 oligomers (+) were calculated using the calibration
curve (Table 4. 1). The number of monomer units for each oligomer is shown above the
marker. (B) CT663 samples were run in 50 mM potassium-sodium phosphate, pH 7. 3
buffer (solid gray line) with 0. 01% Triton X-100 (dotted gray line) and 1% PEG (dashed
gray line). The predicted elution volumes for CT663 oligomers (+) are shown as in (A).
Each sample was 50 L of 81 M CT663 in 50 mM K-Na phosphate, pH 7. 3 buffer,
except for the sample run in 10 mM SDS/Tris buffer. This sample was diluted by a factor
of 4 with the running buffer to avoid SDS-phosphate precipitation. The absorbance
values for this sample were multiplied by 4 for direct comparison to the other samples.
Table 4-1 This table summarized the resulting oligomeric state of CT663 and
Scc1/CT663 complex in different buffer conditions.
Sample
(uM)
CT663
(152)
Scc1:CT663
(133)

Sample Buffer
20 mM sodium phosphate,
300 mM imidazole, 300 mM
NaCl, pH 8. 0
20 mM sodium phosphate,
300 mM imidazole, 300 mM
NaCl, pH 8. 0

Running Buffer
20 mM Tris, 150 mM
NaCl, pH 8. 0
20 mM Tris, 150 mM
NaCl, pH 8. 0

Column/Sample
volume
HiPrep
Sephacryl S-100
HR/ 1 mL
HiPrep
Sephacryl S-100
HR/ 1 mL
HiPrep
Sephacryl S-100
HR/ 1 mL
Enrich 70 SEC/
50 uL

Results
hexamer,
dimer
heterotetramer

Scc1:CT663
(27)

20 mM sodium acetate, pH
4. 5

20 mM sodium
acetate, pH 4. 5

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

20 mM Tris, pH 7. 4

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

50 mM K-Naphosphate, pH 7. 3

Enrich 70 SEC/
50 uL

dimer

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

1 mM SDS, 20 mM
Tris, pH 7. 4

Enrich 70 SEC/
50 uL

apparent
pentamer

CT663 (20)

50 mM K-Na-phosphate, pH
7. 3

10 mM SDS, 20 mM
Tris, pH 7. 4

Enrich 70 SEC/
50 uL

apparent
pentamer
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heterodimer
trimer

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

CT663 (81)

50 mM K-Na-phosphate, pH
7. 3

0. 01% Triton X-100,
20 mM Tris, pH 7. 4
0. 01% Triton X-100,
50 mM K-Naphosphate, pH 7. 3
1% PEG, 50 mM KNa-phosphate, pH 7. 3

Enrich 70 SEC/
50 uL

apparent
tetramer

Enrich 70 SEC/
50 uL

apparent
dimer

Enrich 70 SEC/
50 uL

apparent
dimer

4. 3. 6 SPR analysis of Ct663/Scc1 binding to CopN
SPR was carried out at varies concentrations of ligand and analyte to optimize
the experiment. The Scc1/CT663 ligand concentration was 4 nM. The serial analyte
concentrations used were 2. 5, 5, 10, 20, and 40 nM of CopN. Raw data was collected
in the form of a sensogram which plots response units (RU) vs time. The spectra
corresponding to the blanks and the sample are automatically aligned for subtraction.
The data is first manually processed by selecting which blanks to subtract from the
sample run. Sharp peaks, artifacts that occur during injection, are removed from the
resulting spectrum. The BIAevaluation software was used to fit the data to a curve
based on a 1:1 binding motif. The rate of association and dissociation of the
Scc1/CT663 complex and CopN is 1. 01 x 105 +/- 0. 02 x 105 1/Ms and 3. 04 x 10-4 +/0. 16 x 10-4 1/s respectively. The equilibrium dissociation constant is 3. 02 +/- 0. 17 nM,
which suggest strong binding between CopN and the Scc1/CT663 complex.
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Figure 4-8 The SPR sensogram corresponding to the binding event between the
Scc1/CT663 complex and CopN. The calculated Kd=3. 02 +/- 0. 17 nM.
4. 3. 7 The magical CT663 sample from never never land
CT663 prepared by our collaborators was sent to us for HSQC analysis. The
sample was said to have contained 500 µM CT663 without any purification tags and 20
mM sodium acetate at pH 4. 5. This sample is a good candidate for structural analysis
because greater than 90% of the peaks are present. The peaks are well dispersed and
of similar intensity, suggesting that the protein is fold and possibly in monomeric form.
This spectrum has not been reproducible because the exact conditions were not known.
There was a lack of communication from all parties involved in producing the sample
and obtaining the spectrum. Recent meeting have revealed the appropriate conditions
and attempts to reproduce this spectrum is underway.
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Figure 4-9 1H-15N HSQC of 15N labeled CT663. Each peak corresponds to an 1H-15N
bond from the backbone or a side chain of the protein.
4. 3. 8 NMR buffer optimization for CT663
NMR conditions are optimized to obtain good data. The buffer conditions and
protein concentration are varied until an appropriate spectrum is obtained. A good
HSQC has well resolve peaks of similar intensity, with one peak for every amino acid
except proline. Peak distribution is also important, as it gives information about the
folding of the protein. Well disperse peaks are necessary for a structure determination.
1H-15N HSQC of 15N labeled CT663 in 20 mM sodium phosphate produced peaks that
were dispersed. However, the peak intensities are not similar and not resolved between
8-8. 5 ppm. CT663 in 20 mM tris produce less peaks that vary in intensity, that lack
dispersion. CT663 in 20 mM MES produced peaks that were not dispersed or similar in
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intensity. Tris is a terrible buffer for CT663 because it does not allow for the detection of
an adequate number of amide peaks. There are 142 amino acids that compose CT663,
accounting for the proline residues there should be 139 backbone amide peaks plus
additional side chain peaks. There are more peaks for samples in MES and phosphate
buffer; however, less than 90% of the amide peaks accounted. Peak dispersion is also a
problem, the peaks between 8-8. 5 ppm appear to be overlapping and of different
intensity. These peaks indicated that the protein may be aggregated or unfolded.

Figure 4-10 1H-15N HSQC of 15N labeled CT663 in 20 mM sodium phosphate, 20 mM
tris, and 20 mM MES.
4. 3. 8 15N-CT663:Scc1 NMR analysis
The nature of the CT663/Scc1 complex formation is not known. In an effort to
analyze the effect of Scc1 on CT663, unlabeled Scc1 was added to 15N CT663 and the
1

H-15N HSQC was analyzed. Figure 4-11 shows the overlapped 1H-15N HSQC for 15N
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CT663 and 15N CT663 complexed with Scc1. The spectra show shifts in the amide
peaks that correspond to changes in the backbone structure. The inset of Figure 4-11
shows 13 peaks, 9 of which show varying degrees of shift, signifying a local structural
change.

Figure 4-11 Scc1 perturbs the amide peaks of 15N-CT663. An overlay of 1H-15N HSQC
spectra of 15N-CT663 (red) and 15N-CT663:Scc1 (blue). The inset illustrates the
selective shifts of the putative glycine amide peaks upon binding Scc1. Note: No peaks
are covered by the inset.
4. 3. 9 NMR analysis of the CT663/Scc1 complex
Preliminary NMR data suggested that the Scc1/CT663 complex is a good sample
for structure determination, even though it is ~37 kDa. 15N-Scc1/CT663 was expressed
and purified. The sample was given to Abigael Songok, a graduate student in our lab,
for further analysis. The sample was desalted into 20 mM ammonium acetate at pH 5.

92

5, frozen at -80 oC, and lyophilized. The protein was reconstituted in 20 mM ammonium
acetate and 10 mM DTT at pH 5. 5 with 10% D2O. The sample was concentrated to 250
µL and a 1H-15N HSQC spectrum was collected. The spectrum looks great with 95% of
the amide peaks accounted. The inset of Figure 4-12 shows the peaks are dispersed in
the zoomed view.

Figure 4-12 1H-15N HSQC of 15N labeled Scc1/CT663. The inset is a zoomed view to
show the peak dispersion.
4. 4 Conclusions
The goal of this research is to analyze the structure and ligand interactions of
CT663. CT663 forms a tightly associated complex with Scc1 that cannot be disrupted
with urea. This suggests that hydrophobic interactions play a minor role in keeping the
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complex intact. A CopN pull down assay performed by Li Shen showed that CopN does
not bind CT663 or Scc1 independently, but binds the Scc1/CT663 complex. What
remains unclear is where, spatially, CopN binds the complex. The Phyre2 server
predicted a linear structure, where CopN is bound mainly to CT663, and CT663 is
bound to Scc1. This quaternary structure is possible if the binding of CT663 to Scc1
causes a conformational change of CT663 that is favorable for CopN binding. It is also
possible that there is an area near the interface of the Scc1/CT663 complex where
CopN binds to both proteins. The binding kinetics of Scc1/CT663 was analyzed by SPR.
The interaction between the chaperone complex and CopN is strong bond with a Kd of
3. 02 +/- 0. 17 nM.
In order to obtain good data for structural analysis with NMR, proteins need to be
in their monomeric state or in small (< 25 kDa) multimeric state. The results of the gel
filtration experiments indicate that CT663 forms a dimer or a higher order oligomer
depending on the buffer conditions. Stabilizing the CT663 monomer is not
straightforward. The overlapped peaks in the center of the 1H-15N HSQC of 15N-CT663
in sodium phosphate and tris support the finding that CT663 is aggregating under these
conditions. The 1H-15N HSQC of the 15N-CT663 sample sent to us by our collaborators
showed a very different scenario. The buffer conditions were never replicated because
the protein we produced precipitated when the pH was lowered to 5. After several
meetings, it was discovered that the CT663 in the magical sample lacked the His-tag
used for purification. The His-tag increases the isoelectric point (pI) of CT663 causing it
to precipitate at pH 5 and may also be the source of the aggregation issues. The CT663
that is in complex with Scc1 does not have a His-tag, thus sarkosyl was used to
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separate CT663 from the complex for NMR analysis. Abigael Songok is continuing this
work. If the NMR spectra of CT663 cannot be replicated using sarkosyl to purify the
protein, then CT663 without the His-tag can be produced and purified using a
combination of chromatography methods.

Initial NMR experiments showed that when Scc1 is complexes CT663, there is a
localized change in the backbone structure of CT663. In order to get a better
understanding of how the structure of CT663 changes, the structure of the complex will
be analyzed through complete and mixed isotopic labeling. The 1H-15N HSQC of 15N
Scc1/CT663 is very promising—it should lead to a full 3D structure of the complex.
Adding CopN to the isotopically labeled complex may give information, such as the
residues of CT663 and Scc1 that bind CopN and changes to the CT663:Scc1 structure
when CopN is bound. Knowledge of the binding, even between the complex and CopN,
could lead to inhibitors that could be used in conjunction with current therapeutics to
treat Chlamydia trachomatis.
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Supplementary Figures

Supplementary Figure 1. Ni-affinity purified, resolubilized pellet from the expression of
CREB1-Q2-bZIP (pET-28b-CREB1-Q2-bZIP) without (lane1) and with (lane2) coexpression of OGT (pET-43. 1-OGT) in E. coli BL21-Gold(DE3) analyzed with (a)
Coomassie-stained SDS-PAGE and (b) anti-O-GlcNAc MAb CTD 110. 6 western blot.
HEWL, ovalbumin, and protein ladder are shown in the last three lanes, respectively.
HEWL acts as a positive control for the western blot because the secondary antibody
(DyLight 550-conjugate Goat anti-Mouse IgG) binds non-specifically to HEWL. Residual
HEWL can be seen in lanes 1 and 2 because it was used to lyse the cells in these
preparations. HEWL was not used to lyse cells in any of the other experiments
presented in this manuscript because of its interference in western blot analysis. The
western blot of Q2-bZIP (lanes 1 and 2) demonstrates that OGT is modifying the protein
with O-GlcNAc, consistent with the analysis of Q2-bZIP in the lectin blot in Figure 2. The
pellets were resolubilized in 6 M urea, centrifuged at 14,000 g at 4 °C for 30 min. Q2bZIP was purified from the supernatant using a Bio-Rad BioLogic DuoFlow
chromatography system with a 1 mL His-Select Ni-affinity gel column. After loading the
supernatant, the column was washed with 10 mL of 6 M urea in buffer (50 mM sodium
phosphate, 300 mM NaCl, pH 8. 0), 30 mL gradient (6 – 0 M urea in buffer) at a flow
rate of 0. 1 mL/min, 10 mL of buffer, and 10 mL of 300 mM imidazole in buffer.
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Supplementary Figure 2. The CXC fractions of cleared lysate from a culture of BL21Gold(DE3) cells expressing empty pET-28b were analyzed using the MU-GlcNAc wellplate assay with the β-N-acetylglucosaminidase negative (-) and positive (+) controls.
The active CXC fractions (#4-16) were combined and used to determine the enzyme
kinetic parameters and activity towards the glycopeptide. Error bars represent the
standard deviation of three replicate samples. The positive control intensity was
truncated to better visualize the sample data.

Supplementary Figure 3. Velocities of pNP-GlcNAc hydrolysis by E. coli β-Nacetylglucosaminidase, partially purified with CXC from BL21-Gold(DE3) cleared lysate,
at varying pNP-GlcNAc concentrations. The velocities (nmoles of nitrophenolate formed
per mL of fraction/min) were calculated from the absorbance at 405 nm of samples
measured after 4, 9, and 14 min of reaction time. The curve was fitted to the MichaelisMenten equation (1) using nonlinear regression analysis to give a Km value of 0. 35 mM.
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Supplementary Figure 4. Full 1H NMR spectra of samples from testing the E. coli β-Nacetylglucosaminidase activity of CXC fractions towards the synthetic O-GlcNAcmodified peptide, SVES(β-O-GlcNAc)GSADAK-NH2. Each spectrum was treated
identically for direct comparison.
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Supplementary Figure 5. Cleared lysate from cultures of (a) ∆nagZ K12 strain and (b)
parent K12 strain were separated with CXC and analyzed with the MU-GlcNAc wellplate assay with the β-N-acetylglucosaminidase positive control (+) and negative control
(-). Error bars represent the standard deviation of three replicate samples. The positive
control intensity was truncated to better visualize the sample data.
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Supplementary Figure 6. Full 1H NMR spectra of samples from testing for E. coli β-Nacetylglucosaminidase activity in ∆nagZ K12 lysate towards the synthetic O-GlcNAcmodified peptide, SVES(β-O-GlcNAc)GSADAK-NH2. Each spectrum was treated
identically for direct comparison.
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